A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone
Phase: PHASE3
Conditions: Contraception
Sponsor: Estetra

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 1 of 114 
1 
TITLE PAGE 
Clinical Trial Protocol: MIT-Es0001-C302 
Study Title: 
A Multicenter, Open-label, Single-Arm Study to Evaluate the 
Contraceptive Efficacy and Safety of a Combined Oral 
Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone 
Study Short Title: 
E4 FREEDOM (Female Response concerning Efficacy and safety of 
Estetrol/Drospirenone as Oral contraceptive in a Multicenter study) 
Study Number: 
MIT-Es0001-C302 
ClinicatTrials.gov 
registration No. 
NCT02817841 
IND Number: 
110,682 
Investigational 
Product: 
15 mg Estetrol/3 mg Drospirenone 
Indication: 
Prevention of pregnancy 
Sponsor: 
Estetra SPRL 
Rue Saint Georges 5-7 
4000 Liège 
Belgium 
Telephone: +32 4 349 28 22 
Fax: +32 4 349 28 21 
Safety Monitor: 
PRA Health Sciences  
PRA Pharmacovigilance Department  
Telephone: +1 (800) 772-2215 
Fax: +1 (888) 772-6919 
Email: CHOSafety@prahs.com 
Original Protocol Date: 
07 June 2016 
 
Final Version 1.1 
Amendment 1.0 
 
Date 
14 December 2016 
Amendment 1.1 
 
Date 
10 July 2017 
 
 
Confidentiality Statement 
This document is a confidential communication of the Sponsor.  Acceptance of this document signifies agreement 
by the recipient that no unpublished information contained within will be published or disclosed to a third party 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 2 of 114 
without prior written approval, except that this document may be disclosed to an Institutional Review Board or 
Ethics Committee under the same confidentiality conditions.  

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 3 of 114 
2 
SYNOPSIS 
Sponsor: 
Estetra SPRL 
Investigational Product: 
15 mg Estetrol (E4)/3 mg Drospirenone (DRSP)  
Study Title: 
A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and 
Safety of a Combined Oral Contraceptive (COC) Containing 15 mg E4 and 3 mg DRSP. 
Study Number: 
MIT-Es0001-C302 
Study Phase:  
Phase 3 
Primary Objective – Efficacy:  
To evaluate the contraceptive efficacy of 15 mg E4/3 mg DRSP using the Pearl Index in 
subjects aged 16 to 35 years, inclusive, at the time of screening. 
 
Primary efficacy endpoint:   
The number of on-treatment pregnancies as assessed by the Pearl Index in subjects aged 16 
to 35 years, inclusive, at the time of screening.  
Secondary Efficacy Objectives: 
1. To evaluate the contraceptive efficacy of 15 mg E4/3 mg DRSP using the method 
failure Pearl Index and  life-table analysis in subjects aged 16 to 35 years, inclusive, 
at the time of screening. 
2. To evaluate the contraceptive efficacy of 15 mg E4/3 mg DRSP using the Pearl 
Index, the method failure Pearl Index and life-table analysis in the overall study 
population. 
Secondary efficacy endpoints: 
1. The number of on-treatment pregnancies as assessed by the method failure Pearl 
Index and the cumulative pregnancy rate in subjects aged 16 to 35 years, inclusive, 
at the time of screening. 
2. The number of on-treatment pregnancies as assessed by the Pearl Index, the method 
failure Pearl Index and the cumulative pregnancy rate in the overall study population.  
Other Secondary Objectives: 
1. To evaluate cycle control and bleeding pattern associated with 15 mg E4/3 mg 
DRSP.  
2. To evaluate general safety of 15 mg E4/3 mg DRSP. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 4 of 114 
3. To evaluate the impact of 15 mg E4/3 mg DRSP on physical, psychological, and 
social functioning and well-being. 
4. To assess the effect of various individual characteristics/ covariates (body weight, 
race, smoking, and fed/fasted condition) on the pharmacokinetics (PKs) of 15 mg 
E4/3 mg DRSP (Population PK Substudy). 
Other secondary endpoints: 
1. Cycle control and bleeding patterns based on vaginal bleeding information recorded 
daily by the subjects in the diaries. 
2. Safety data in the overall study population obtained from routine laboratory 
parameters, vital signs, and physical, gynecological and breast examinations, 
evaluated as the number, frequency, type and intensity of adverse events (AEs) and 
serious adverse events (SAEs). 
3. Change from baseline to end of treatment in the different items of well-established 
questionnaires. 
4. Plasma E4 and DRSP concentration data from a subset of approximately 500 subjects 
for the development of a population PK model (Population PK Substudy). 
Study Design: 
Multicenter, open-label, single-arm study. 
Study Population:  
Approximately 2000 healthy female subjects at risk for pregnancy, between 16 and 50 years 
old, inclusive (at the time of screening), and requesting contraception will be enrolled in the 
study and initiate the investigational product. In total 1800 subjects will be 16 to 35 years 
old, inclusive (at the time of screening). Recruitment may be stopped when 2000 subjects 
have initiated the investigational product if the required number of subjects for the primary 
analysis (1800 subjects in the age group up to and including 35 years) has been reached. 
Recruitment in the age group > 35 years will be stopped when 200 subjects have initiated 
the investigational product. Approximately 500 of these subjects will be included in the 
Population PK Substudy. 
Study Locations:  
This clinical study will be conducted in up to approximately 80 centers in North America 
(United States of America and Canada).  
Eligibility criteria: 
 Inclusion criteria: 
A subject will be considered for inclusion in the study if she meets all of the following 
criteria: 
1. Heterosexually active female at risk for pregnancy and requesting contraception. 
2. Negative serum pregnancy test at subject screening. 
3. Aged 16 to 50 years (inclusive) at the time of signing the informed consent (IC). 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 5 of 114 
4. Willing to use the investigational product as the primary method of contraception for 
13 consecutive cycles. 
5. Good physical and mental health on the basis of medical, surgical and gynecological 
history, physical examination, gynecological examination, clinical laboratory, and 
vital signs. 
6. Body mass index (BMI) below or equal to (≤) 35.0 kg/m2. 
7. Able to fulfill the requirements of the protocol and have indicated a willingness to 
participate in the study by providing written IC. 
8. Willing and able to complete the diaries and questionnaires. 
 Exclusion Criteria 
A subject will be excluded from participation if she meets any of the following criteria: 
1. For subjects who are not using hormonal contraception at screening, a menstrual 
cycle length shorter than 21 days or longer than 35 days.  
2. Clinically relevant abnormal laboratory result at screening in the opinion of the 
investigator with an understanding of the central laboratory normal range. 
3. Known hypersensitivity to any of the investigational product ingredients. 
4. Currently pregnant or with the intention to become pregnant during the course of the 
study. 
5. Currently breastfeeding or before two spontaneous menstruations have occurred 
after cessation of breastfeeding prior to start of trial medication. 
6. Less than 6 weeks since last delivery/2nd trimester abortion and before spontaneous 
menstruation has occurred following a delivery or 2nd trimester abortion. 
7. Smoking nicotine-containing products if > 35 years old. 
8. Dyslipoproteinemia requiring active treatment with antilipidemic agent.  
9. Diabetes mellitus with vascular involvement (nephropathy, retinopathy, neuropathy, 
other) or diabetes mellitus of more than 20 year duration. 
10. Any arterial hypertension (controlled and uncontrolled) defined by blood pressure 
values of: 
a. systolic blood pressure ≥ 140 mmHg and/or,  
b. diastolic blood pressure ≥ 90 mmHg.  
11. Personal history of deep vein thrombosis or pulmonary embolism. 
12. Current prolonged immobilization or major surgery with prolonged immobilization 
planned in the next 12 months. 
13. Known inherited or acquired hypercoagulopathies (e.g. antiphospholipid syndrome) 
or thrombogenic mutations (e.g. factor V Leiden, prothrombin mutation, protein S, 
protein C and antithrombin deficiencies). 
14. Current treatment with anticoagulants. 
15. Presence or history of arterial thromboembolism (e.g. angina pectoris, ischemic heart 
disease, cerebral stroke or transient ischemic attack). 
16. Complicated valvular heart disease (pulmonary hypertension, atrial fibrillation, 
subacute bacterial endocarditis). 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 6 of 114 
17. History of pregnancy-related cardiomyopathy or moderately or severely impaired 
cardiac function. 
18. Systemic lupus erythematosus. 
19. Presence or history of migraine with aura at any age or migraine without aura if >35 
years old. 
20. Within the past 6 months, has had undiagnosed (unexplained) abnormal vaginal 
bleeding, or any abnormal bleeding that is expected to recur during the trial (e.g., 
bleeding from cervical polyp, recurrent bleeding after sex). 
21. In case of Chlamydial or gonococcal infection at screening, when no treatment 
initiated at subject enrollment. 
22. Abnormal Pap test (written documentation of prior test or test at screening exam) 
based on the following criteria: 
 Pap test in the past 18 months with ASC-US unless: 
o less than 21 years of age; or 
o a repeat Pap test at least 6 months later was normal; or 
o reflex HPV testing was performed and was negative for high-risk 
oncogene human-papilloma-virus (HPV). 
 Pap test in the past 18 months with LSIL unless less than 21 years of age. 
 Pap test in the past 18 months with ASC-H, atypical glandular cells, HSIL or 
malignant cells. 
23. Presence of an undiagnosed breast mass. 
24. Current symptomatic gallbladder disease. 
25. History of COC-related cholestasis. 
26. Presence or history of severe hepatic disease as long as liver function values have 
not returned to normal. 
27. Presence or history of pancreatitis if associated with hypertriglyceridemia.  
28. Porphyria. 
29. Presence or history of hepatocellular adenoma or malignant liver tumor. 
30. Renal impairment (GFR < 60 mL/min/1.73m²). 
31. Hyperkaliemia or presence of conditions that predispose to hyperkaliemia such as 
renal impairment, hepatic impairment, adrenal insufficiency and women receiving 
daily, long-term treatment for chronic conditions or diseases with medications that 
may increase serum potassium concentration (e.g. ACE inhibitors, angiotensin-II 
receptor antagonists, potassium-sparing diuretics, potassium supplementation, 
heparin, aldosterone antagonist and non-steroidal anti-inflammatory drugs). 
32. History of organ transplantation within 5 years before screening or chronic disease 
potentially necessitating organ transplantation during the anticipated course of the 
study. 
33. Presence or history of hormone-related malignancy. 
34. History of non-hormone-related malignancy within 5 years before screening. 
Subjects with a non-melanoma skin cancer are allowed in the study. 
35. Current regular use or regular use within 1 month prior to subject enrollment of drugs 
potentially triggering interactions with COCs including but not limited to: 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 7 of 114 
a. Cytochrome P450 3A4 (CYP 3A4) inducers: barbiturates, primidone, 
bosentan, 
felbamate, 
griseofulvin, 
oxcarbazepine, 
topiramate, 
carbamazepine, phenytoin, rifampicin, St John’s wort. 
b. CYP 3A4 inhibitors: azole antifungals, phenylbutazone, modafinil,  
cimetidine, verapamil, macrolides, diltiazem and grapefruit juice. 
c. Human immunodeficiency virus (HIV)/Hepatitis C virus (HCV) protease 
inhibitors and non-nucleoside reverse transcriptase inhibitors. 
36. Use of an injectable hormonal method of contraception within 10 months (300 days) 
prior to screening of an injection with a 3-month duration, within 6 months (180 
days) prior to screening of an injection with a 2-month duration, within 3 months (90 
days) prior to screening of an injection with a 1-month duration. 
37. History of alcohol or drug abuse (including laxatives) within 12 months prior to 
screening. 
38. Any prior procedure, disease or condition that could result in altered absorption, 
excessive accumulation, impaired metabolism, or altered excretion of the 
investigational product. 
39. Uncontrolled thyroid disorders. 
40. Participation in another investigational drug clinical study within 1 month (30 days) 
or have received an investigational drug within the last 3 months (90 days) prior to 
study entry. Subjects who participated in an oral contraceptive clinical study, using 
FDA/EU approved active ingredients, may be enrolled 2 months (60 days) after 
completing the preceding study.  
41. Sponsor, the Contract Research Organization (CRO) or Investigator’s site personnel 
directly affiliated with this study. 
42. Is judged by the Investigator to be unsuitable for any reason. 
Investigational Product; Dose; and Mode of Administration: 
The investigational product is a 15 mg E4/3 mg DRSP tablet administered orally once daily 
in a 24/4-day regimen (i.e. 24 days of active tablets followed by 4 days of placebo tablets). 
Duration of the study:   
Overall treatment duration is up to thirteen 28-day cycles, i.e., 12 months. 
Those subjects who discontinue due to a pregnancy wish will be followed-up for a maximum 
of one year after study discontinuation for return of spontaneous menstruation and until 
pregnancy or initiation of a contraceptive method (whichever occurs first). 
Statistical Methods: 
For the efficacy analyses, the pregnancy rates will be expressed as: 
- 
Pearl Index (number of pregnancies per 100 woman years due to method and user 
failure) with a two-sided 95% confidence interval (CI); 
- 
Method failure Pearl Index (number of pregnancies per 100 woman years due to 
method failure only) with a two-sided 95% CI; 
- 
Life-table analysis (cumulative pregnancy rate). 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 8 of 114 
For Pearl index calculations, thirteen 28-day cycles constitute one woman-year. 
Primary Efficacy Analysis:  
Pearl Index for subjects aged 16 to 35 years, inclusive, at the time of screening. 
 
Secondary Efficacy Analyses: 
 Method failure Pearl Index and life-table analysis for subjects aged 16 to 35 years, 
inclusive, at the time of screening. 
 Pearl Index, method failure Pearl Index and life-table analysis for the overall study 
population (16 to 50 years). 
 
Additional Summaries: 
 Occurrence of scheduled and unscheduled vaginal bleeding/spotting in the overall 
study population. 
 Compliance analysis based on tablet intake in the overall study population. 
 Number, frequency, type and intensity of AEs and SAEs in the overall study 
population. 
 Descriptive summaries for other safety parameters including clinical labs, physical 
exams, gynecological exams, and vital signs. 
 Descriptive summaries of scores of well-being questionnaires. 
 Population PK model (using plasma E4 and DRSP concentration data from a subset 
of approximately 500 subjects). PK parameters will include, but not be limited to: 
o Apparent clearance (CL/F). 
o Central volume of distribution (V/F). 
o Lag time of Absorption (tlag), if necessary. 
o Relative bioavailability for fed vs fasted state 
o Maximum concentration (Cmax). 
o Time to Cmax (Tmax). 
o Extent of exposure for the dosing interval (AUCtau). 
o Terminal half-life (t1/2). 
Continuous variables will be summarized using descriptive statistics (mean, median, 25th 
percentile, 75th percentile, standard deviation (SD), standard error of the mean (SEM), 
minimum, maximum, and number of subjects) and all categorical variables will be 
summarized using frequency distributions (number and percentage of subjects), as 
appropriate. 
Initial estimates of PK parameters (e.g., CL/F, V/F, tlag) will be determined using 
exploratory compartmental analyses. These estimates will be employed to build an 
appropriate population PK model. The primary parameters will include (but not be limited 
to) CL/F, V/F, tlag and relative bioavailability for fed vs fasted. The impact of individual 
characteristics (body weight, race, smoking, and fed/fasted condition) on the PK parameters 
will be explored and included in the population model if significant. Individual estimates of 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 9 of 114 
the parameters and additional PK variables will be generated based on the population model. 
Covariate analyses will be performed separately for the PK of E4 and DRSP. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 10 of 114 
3 
TABLE OF CONTENTS 
1 
TITLE PAGE .....................................................................................................................1 
2 
SYNOPSIS .........................................................................................................................3 
3 
TABLE OF CONTENTS .................................................................................................10 
4 
LIST OF ABBREVIATIONS ..........................................................................................14 
5 
DEFINITION OF THE TERMS ......................................................................................16 
6 
STUDY ADMINISTRATIVE STRUCTURE .................................................................17 
7 
INTRODUCTION ...........................................................................................................19 
7.1 
Background ............................................................................................................19 
7.2 
Prior Clinical Experience .......................................................................................20 
8 
STUDY OBJECTIVES ....................................................................................................22 
8.1 
Primary Objective(s) ..............................................................................................22 
8.2 
Secondary Efficacy Objective(s) ...........................................................................22 
8.3 
Other Secondary Objective(s) ................................................................................22 
9 
INVESTIGATIONAL PLAN ..........................................................................................23 
9.1 
Overall Study Design and Plan ..............................................................................23 
9.2 
Rationale for Study Design ....................................................................................24 
9.3 
Selection of Study Population ................................................................................24 
9.3.1 
Inclusion Criteria .........................................................................................25 
9.3.2 
Exclusion Criteria ........................................................................................25 
9.3.3 
Subject Identification ...................................................................................27 
9.4 
Study Treatment .....................................................................................................28 
9.4.1 
Identity of Investigational Products .............................................................28 
9.4.1.1 
Labeling .............................................................................................28 
9.4.1.2 
Storage and Drug Accountability .......................................................29 
9.4.2 
Method of Assigning Subjects to Treatment ...............................................29 
9.4.3 
Treatment Compliance .................................................................................30 
9.4.4 
Selection of Doses and Timing of Administration in the Study ..................30 
9.4.4.1 
Instructions for starting the first pack of tablets ................................30 
9.4.4.2 
Dosing Instructions ............................................................................31 
9.4.4.3 
Instructions in case of missed tablet(s) or in conditions potentially 
reducing the contraceptive efficacy ...................................................31 
9.4.4.4 
In case of short-term intake of drugs that may decrease the 
efficacy of the COC ...........................................................................33 
9.4.4.5 
Use of the investigational product in case of bleeding/spotting 
episode ...............................................................................................33 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 11 of 114 
9.4.4.6 
Use of the investigational product in the event of a missed 
menstrual period.................................................................................33 
9.4.5 
Blinding........................................................................................................33 
9.4.6 
Restrictions ..................................................................................................33 
9.4.6.1 
Prior and Concomitant Therapy .........................................................33 
9.4.6.2 
Condoms and other contraceptive methods .......................................35 
9.4.7 
Treatment beyond the clinical trial ..............................................................35 
9.5 
Study Activities ......................................................................................................35 
9.5.1 
Visit 1: Screening Visit ................................................................................35 
9.5.2 
Visit 2: Subject Enrollment ..........................................................................37 
9.5.3 
Treatment Period (from Cycle 1 Day 1 until Cycle 13 Day 28) ..................38 
9.5.3.1 
Visit 3 (Cycle 2, between Day 1 and Day 14) ...................................38 
9.5.3.2 
Visit 4 (Cycle 4, between Day 1 and 14) ...........................................39 
9.5.3.3 
Visit 5 (Cycle 7, between Day 1 and 14) ...........................................40 
9.5.3.4 
Visit 6 (Cycle 10, between Day 1 and 14) .........................................40 
9.5.3.5 
Visit 7 (Cycle 14, between Day 16 and 23), End of Treatment 
Visit ....................................................................................................41 
9.5.4 
Early Termination Visit ...............................................................................42 
9.5.5 
Unscheduled Visit ........................................................................................43 
9.6 
Study Variables and Procedure Descriptions .........................................................43 
9.6.1 
Subject Diary ...............................................................................................43 
9.6.2 
Efficacy Assessments...................................................................................44 
9.6.2.1 
Pregnancy Testing and Estimating Date of Conception ....................44 
9.6.2.2 
Pregnancy Reporting ..........................................................................45 
9.6.3 
Safety Variables ...........................................................................................46 
9.6.3.1 
Adverse Events ..................................................................................46 
9.6.3.2 
Extent of Exposure .............................................................................51 
9.6.3.3 
Clinical Laboratory Evaluations ........................................................51 
9.6.3.4 
Physical Examination.........................................................................52 
9.6.3.5 
Height, Weight and Body Mass Index ...............................................52 
9.6.3.6 
Gynecological Examination, Chlamydia test, Gonorrhea test and 
Cervical Cytology ..............................................................................52 
9.6.3.7 
Vital Signs ..........................................................................................53 
9.6.4 
Other Evaluations.........................................................................................53 
9.6.4.1 
Incidence of vaginal bleeding/spotting ..............................................54 
9.6.4.2 
Population Pharmacokinetic Substudy ..............................................54 
9.6.4.3 
Compliance ........................................................................................55 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 12 of 114 
9.6.4.4 
Demographics ....................................................................................55 
9.6.4.5 
Prior and Concomitant Medication Use .............................................55 
9.6.4.6 
Medical/Surgical History ...................................................................56 
9.6.4.7 
Gynecological History .......................................................................56 
9.6.4.8 
Pregnancy Risk and Back-up Contraception Use ..............................57 
9.6.4.9 
Contraceptive Counseling ..................................................................57 
9.6.4.10 
Acceptability of Trial Medication ......................................................58 
9.6.4.11 
Subjects’ well-being...........................................................................58 
9.6.4.12 
Return of spontaneous menstruation and return to fertility ...............58 
10 ETHICS............................................................................................................................59 
10.1 
Ethics Committee ...................................................................................................59 
10.2 
Ethical Conduct of Study .......................................................................................59 
10.3 
Subject Information and Consent...........................................................................59 
10.4 
Subject Confidentiality ..........................................................................................60 
11 QUALITY CONTROL AND ASSURANCE .................................................................61 
12 PLANNED STATISTICAL METHODS ........................................................................62 
12.1 
Determination of Sample Size ...............................................................................62 
12.2 
Analysis Populations and Datasets ........................................................................62 
12.3 
General Statistical Procedures ...............................................................................63 
12.4 
Efficacy Analyses ..................................................................................................63 
12.4.1 
Efficacy Endpoints .......................................................................................64 
12.4.2 
Statistical Analysis .......................................................................................64 
12.4.2.1 
Confidence Intervals for the Pearl Indices .........................................64 
12.4.2.2 
Life-Table Rates.................................................................................64 
12.4.3 
Statistical Subgroup Analyses......................................................................65 
12.5 
Safety Analyses ......................................................................................................65 
12.5.1 
Adverse Events ............................................................................................65 
12.5.2 
Extent of Exposure .......................................................................................66 
12.5.3 
Clinical Laboratory Evaluations ..................................................................66 
12.5.4 
Physical examination ...................................................................................66 
12.5.5 
Gynecological examination .........................................................................67 
12.5.6 
Vital Signs ....................................................................................................67 
12.5.7 
Height, Weight and BMI..............................................................................67 
12.6 
Other Assessments or Analyses .............................................................................67 
12.6.1 
Bleeding and spotting ..................................................................................67 
12.6.2 
Disposition ...................................................................................................69 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 13 of 114 
12.6.3 
Demographic and Other Pre-treatment Characteristics ...............................69 
12.6.4 
Prior and Concomitant Medications ............................................................69 
12.6.5 
Treatment Compliance .................................................................................70 
12.6.6 
Protocol Deviations ......................................................................................70 
12.6.7 
Quality of Life..............................................................................................70 
12.6.8 
Follow-Up Evaluations ................................................................................70 
12.6.9 
Population Pharmacokinetic Substudy ........................................................71 
13 STUDY MANAGEMENT ..............................................................................................72 
13.1 
Monitoring .............................................................................................................72 
13.2 
Protocol amendments .............................................................................................72 
13.3 
Protocol deviations.................................................................................................73 
13.4 
Withdrawal of Subjects ..........................................................................................73 
13.5 
Termination of the Study .......................................................................................74 
14 DOCUMENTATION REQUIREMENTS AND RECORDKEEPING ...........................75 
14.1 
Source Documentation, Data access and Monitoring ............................................75 
14.2 
Data Capture in electronic CRFs and Discrepancy Management ..........................75 
14.3 
RECORD KEEPING .............................................................................................75 
15 OTHER INFORMATION ...............................................................................................77 
15.1 
Financing and Insurance ........................................................................................77 
15.2 
Publication and Disclosure Policy .........................................................................77 
16 REFERENCE LIST .........................................................................................................78 
17 APPENDICES .................................................................................................................79 
 
List of tables 
Table 1: Bleeding and spotting definitions ..................................................................68 
Table 2: Schedule of Events .........................................................................................80 
 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 14 of 114 
4 
LIST OF ABBREVIATIONS  
ACE 
Angiotensin converting enzyme 
AE 
Adverse event 
ALP 
Alkaline phosphatase 
ALT 
Alanine aminotransferase 
APC 
Active protein C 
ASC-H 
Atypical squamous cells with possible high-grade squamous 
intraepithelial lesion 
ASC-US 
Atypical squamous cells of undetermined significance 
AST 
Aspartate aminotransferase 
BMI 
Body mass index 
CBG 
Corticosteroid binding globulin 
CFR 
Code of federal regulations 
CI 
Confidence interval 
CIN 
Cervical intraepithelial neoplasia 
CIS 
Carcinoma in situ 
COC 
Combined oral contraceptive 
CRO 
Contract research organization 
CYP 3A4 
Cytochrome P450 3A4 
DRSP 
Drospirenone 
E2 
Estradiol 
E2V 
Estradiol valerate 
E4 
Estetrol 
eCRF 
Electronic case report form 
EE 
Ethinylestradiol 
EMA 
European medicines agency 
FDA 
Food and drug administration 
EMR 
Electronic medical records 
FSH 
Follicle stimulating hormone 
GCP 
Good clinical practice 
GFR 
Glomerular filtration rate 
GGT 
Gamma-glutamyl transferase 
GMP 
Good manufacturing practice 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 15 of 114 
HCV 
Hepatitis C virus 
HDL 
High density lipoprotein 
HIV 
Human immunodeficiency virus 
IB 
Investigator’s brochure 
IC 
Informed consent 
ICH 
International conference on harmonization of technical 
requirements for registration of pharmaceuticals for human use 
IRB 
Institutional review board 
ITT 
Intent-to-treat 
IUD 
Intrauterine device 
IUS 
Intrauterine system 
IWRS 
Interactive web response system 
LDH 
Lactate dehydrogenase 
LDL 
Low density lipoprotein 
LGSIL 
Low-grade squamous intraepithelial lesion 
LH 
Luteinizing hormone 
LNG 
Levonorgestrel 
MedDRA 
Medical dictionary for regulatory activities 
PP 
Per-protocol 
Q-LES-Q-SF 
Quality of life enjoyment and satisfaction questionnaire short 
form 
RP 
Reference period  
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SD 
standard deviation 
SEM 
standard error of mean 
SHBG 
Sex hormone binding globulin 
STI 
Sexually transmitted infection 
TEAE 
Treatment emergent adverse event 
t-PA 
Tissue-type plasminogen activator 
VTE 
Venous thromboembolism 
WHO 
World health organization 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 16 of 114 
5 
DEFINITION OF THE TERMS 
Barrier Contraception 
Birth control methods which physically block or otherwise prevent 
sperm from entering the uterus and reaching the egg for fertilization, 
including spermicides, sponges, condoms, diaphragms, and cervical 
caps. 
Pre-treatment pregnancy 
Pre-treatment pregnancies are pregnancies with an estimated date of 
conception before the first intake of trial medication. 
On-treatment pregnancy 
On-treatment pregnancies are pregnancies with an estimated date of 
conception within the in-treatment period i.e. Day 1 to 7 days after 
the last intake of investigational product (whether active or inactive 
tablet). 
Post-treatment pregnancy 
Post-treatment pregnancies are pregnancies with an estimated date 
of conception after the in-treatment period i.e. more than 7 days after 
the intake of investigational product (whether active or inactive 
tablet). 
Pearl Index 
The Pearl index is defined as the number of pregnancies per 100 
woman-years of exposure: 
𝑃𝑒𝑎𝑟𝑙 𝐼𝑛𝑑𝑒𝑥
=
1300 ×  number of "on −treatment" pregnancies
number of women −28 −day equivalent cycles of treatment 
 
The Pearl Index calculation only takes into account at risk cycles 
defined as cycles during which: 
- 
no other contraceptive methods were used and, 
- 
the subject confirms that she has had intercourse. 
Method failure Pearl Index 
The method failure Pearl Index is calculated using the same method 
used for the Pearl Index, but includes only those pregnancies that 
were classified as method failure and not the pregnancies due to user 
failure, i.e. incorrect intake of the contraceptive method.  
Starters/Switchers 
- Starters: all subjects who have not used hormonal contraceptive(s) 
for 3 months before first investigational treatment intake. 
- Switchers: all subjects who have used a hormonal contraceptive 
during the 3 months before first investigational treatment intake. 
- True new users: all subjects who have never been using hormonal 
contraception. 
Vaginal bleeding 
Evidence of vaginal blood loss that requires the use of sanitary 
protection with a tampon, pad or pantyliner. 
Vaginal spotting 
Evidence of minimal vaginal blood loss that does not require new 
use of sanitary protection, including pantyliners. 
 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 17 of 114 
6 
STUDY ADMINISTRATIVE STRUCTURE 
The study will be performed in approximately 80 centers in North America with approximately 
90% of subjects in United States of America and 10% of subjects in Canada.   
Estetra SPRL is the Sponsor of this study.   
The Contract Research Organization (CRO) PRA Health Sciences will perform the following 
activities on behalf of the Sponsor for this study: regulatory submissions, project management 
(including site contracts, third party vendor management, etc.), clinical operations, clinical 
monitoring, medical and safety monitoring, data management, analysis and reporting. 
Central facilities will be used for the analysis and storage of laboratory assessments. Details of 
the central facilities and handling of samples will be provided in separate manuals. 
On the approval date of this protocol, the administrative structure and the external 
organizations supporting the study were as follows: 
Sponsor 
Estetra SPRL 
Rue Saint Georges 5-7 
4000 Liège 
Belgium 
Telephone: +32 4 349 28 22 
Fax: +32 4 349 28 21 
 
CRO  
PRA Health Sciences 
4130 ParkLake Avenue, Suite 400 
Raleigh, NC  27612 
USA 
Telephone: +1 (919) 786-8200 
Fax: +1 (919)786-8201 
 
Central Laboratory 
(for both laboratory 
and Population 
pharmacokinetic 
(PK) Substudy 
sample analysis) 
Eurofins Central Laboratory Lancaster 
2430 New Holland Pike 
Lancaster, PA 17601 
USA 
 
PRA Health Sciences - Early Development Services 
Bioanalytical Laboratory 
11070 Strang Line Road 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 18 of 114 
Lenexa, KS 66215 
USA 
 
 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 19 of 114 
7 
INTRODUCTION 
7.1 Background 
Combined oral contraceptives (COCs) are medications taken orally combining a progestin and 
an estrogen. The function of the progestin is to inhibit ovulation by a central feedback 
mechanism resulting in decreased luteinizing hormone (LH) secretion by the pituitary gland.  
The estrogen component also contributes to contraceptive activity by inhibiting the secretion 
of follicle-stimulating hormone (FSH) but its major function is to provide stability to the 
endometrium and consequently to provide acceptable cycle control and bleeding pattern.  
COCs are widely used in the industrialized world.  They have been shown to be highly effective 
in terms of contraception.  
The potent synthetic estrogen, ethinylestradiol (EE), is the most frequently used estrogen in 
COCs. EE is easily absorbed when administered orally. Products containing EE generally have 
a good bleeding profile; however EE is also responsible for most of the side effects experienced 
by COC users. Among those, a rare but potentially very serious event is venous 
thromboembolism (VTE). The increased risk of thromboembolism among COC users is 
principally due to the strong impact of EE on hepatic synthesis functions, which leads to an 
increased production of several proteins involved in the coagulation and inflammatory 
pathways. As a consequence, an imbalance appears between pro- and anticoagulant circulating 
factors in favor to pro-coagulation. Beside the thromboembolism risk, EE is also associated 
with water retention (responsible of breast tension, edema, weight increase, nausea, headache 
and liability of humor) as well as with an increased risk of cholangiopathy.  
To improve the safety profile of COCs, research and development has focused on two main 
approaches. First, the dose of EE has been progressively lowered from > 75 µg to as low as 
10 µg. As EE doses decrease, the incidence of irregular and potentially unacceptable bleeding 
profiles increases. The second approach has been to replace EE with a naturally occurring 
estrogen: new COCs containing estradiol (E2) or estradiol valerate (E2V) have recently been 
developed, with the prospect of decreasing the metabolic impact from the estrogen component 
of COCs.   
Estetra SPRL is developing a new COC containing a synthetic form of natural estrogen, estetrol 
(E4), in association with drospirenone (DRSP), a well-characterized and widely used 
contraceptive progestin. E4 is only produced by the human fetal liver during pregnancy and 
reaches the maternal circulation through the placenta. E4 has been isolated in maternal urine 
as early as week 9 of gestation. At term, the hormone is found at relatively high concentrations 
(about 1 ng/mL) in maternal plasma and over ten times higher in fetal plasma.  
 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 20 of 114 
7.2 Prior Clinical Experience 
Estetrol  
In two Phase 1 clinical studies (PR3050 and PR3054) performed in healthy postmenopausal 
women, E4 was associated with a good safety and tolerability profile when it was taken orally 
as a single dose up to 100 mg and as daily multiple doses up to 40 mg during 28 consecutive 
days. Oral intake of multiple rising doses of E4 demonstrated an anti-gonadotropic activity 
characterized by a dose-dependent decrease in both FSH and LH levels. This study also 
documented a significant increase in endometrial thickness in accordance with E4’s estrogenic 
actions.  
Estetrol/Drospirenone 
The safety and efficacy of E4 in combination with DRSP were studied in healthy 
premenopausal women enrolled in two Phase 2 clinical studies called ES-C01 and ES-C02. 
Data from ES-C01 showed that 5 or 10 mg E4 combined with 3 mg DRSP administered in a 
24/4-day regimen for three treatment cycles exert a complete inhibition of ovulation.1 Ovarian 
activity decreases with increasing dose of E4. In addition, very limited to no impact on hepatic 
metabolism was observed with the E4/DRSP combinations as demonstrated by measurement 
before and after three treatment cycles of triglycerides2 and surrogate markers of hemostasis 
such as D-dimer, Prothrombin fragment 1+2, inhibitors of coagulation (Active Protein C 
[APC] sensitivity, antithrombin III, APC resistance, protein S activity), liver factors 
(fibrinogen and prothrombin), endothelial factors (E-selectin and tissue-type plasminogen 
activator [tPA]) and carrier proteins (corticosteroid binding globulin [CBG], sex hormone 
binding globulin [SHBG] and ceruloplasmin).2 Decrease from baseline in the carrier proteins 
was noted after one cycle of treatment. These findings suggest limited impact of the E4/DRSP 
combination on the coagulation pathway.  
The combination of 3 mg DRSP with either 15 mg E4 or 20 mg E4 administered in a 24/4-day 
regimen was evaluated in the ES-C02 study, a six-cycle treatment study focusing on vaginal 
bleeding pattern and cycle control. A high rate of expected withdrawal bleeding (96.5%) and 
a low incidence of unscheduled bleeding/spotting episodes (16.9%) were observed with the 
15 mg E4/3 mg DRSP combination. In addition, the E4/DRSP combinations demonstrated a 
good safety and tolerability profile. A low frequency of adverse events (AEs) with the 15 mg 
E4/3 mg DRSP combination was recorded and all AEs were similar to those classically 
observed with COCs. Finally, no ovulations were observed during this study demonstrating 
the potential for high contraceptive reliability of the E4/DRSP combinations studied. 
From the different studies performed thus far with E4, it can be concluded that an E4-
containing COC is well tolerated. No safety concern was observed with any E4 combination. 
However, until further evaluation in larger populations, the classical COC contraindications 
will apply to the 15 mg E4/3 mg DRSP combination. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 21 of 114 
Based on the results obtained from the Phase 2 studies, the regimen of 15 mg E4 combined 
with 3 mg DRSP was selected as the optimal combination (minimum effective dose) for the 
Phase 3 program. 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 22 of 114 
8 
STUDY OBJECTIVES 
8.1 
Primary Objective(s) 
The primary objective of this study is to evaluate the contraceptive efficacy of 15 mg E4/3 mg 
DRSP using the Pearl Index in subjects aged 16 to 35 years, inclusive, at the time of screening. 
8.2 
Secondary Efficacy Objective(s) 
The secondary objectives of this study are: 
1. To evaluate the contraceptive efficacy of 15 mg E4/3 mg DRSP using the method 
failure Pearl Index and life-table analysis in subjects aged 16 to 35 years, inclusive, at 
the time of screening. 
2. To evaluate the contraceptive efficacy of 15 mg E4/3 mg DRSP using the Pearl Index, 
the method failure Pearl Index and life-table analysis in the overall study population. 
8.3 
Other Secondary Objective(s) 
1. To evaluate cycle control and bleeding pattern associated with 15 mg E4/3 mg DRSP. 
2. To evaluate general safety of 15 mg E4/3 mg DRSP.  
3. To evaluate the impact of 15 mg E4/3 mg DRSP on physical, psychological, and social 
functioning and well-being. 
4. To assess the effect of various individual characteristics/ covariates (body weight, race, 
smoking, and fed/fasted condition) on the PKs of 15 mg E4/3 mg DRSP (Population 
PK Substudy). 
 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 23 of 114 
9 
INVESTIGATIONAL PLAN 
9.1 
Overall Study Design and Plan 
This study is a multicenter, open-label, single-arm study. 
The total duration of the study, including the screening, will range from 387 to 467 days for 
the participating subjects, which is approximately a year and one month. Those subjects who 
discontinue due to a pregnancy wish will be followed-up for a maximum of one year after 
study discontinuation for return of spontaneous menstruation and until pregnancy or initiation 
of a contraceptive method (whichever occurs first).  
Approximately 2000 healthy female subjects at risk for pregnancy, between 16 and 50 years 
old (inclusive, at the time of screening), and requesting contraception will be enrolled in the 
study and initiate the investigational product. In total, 1800 subjects will be 16 to 35 years old 
(inclusive). Recruitment may be stopped when 2000 subjects have initiated the investigational 
product if the required number of subjects for the primary analysis (1800 subjects in the age 
group up to 35 years) has been reached. Recruitment in the age group > 35 years will be stopped 
when 200 subjects have initiated the investigational product. 
Eligible subjects will be treated with 15 mg E4/3 mg DRSP for up to 13 consecutive cycles. 
The treatment must be taken once daily at approximately the same time of the day in a 24/4-
day regimen, i.e. 24 active tablets followed by 4 placebo tablets (4-day hormone free interval). 
The primary objective of the study is to evaluate the contraceptive efficacy of the new COC, 
using the Pearl Index calculation (which reflects the pregnancy rate associated with a 
contraceptive method) among the subjects aged 16 to 35 years inclusive.  
The contraceptive efficacy will also be evaluated using the method failure Pearl Index (which 
reflects the pregnancy rate due to method failure only) and life-table analysis in the subjects 
aged 16 to 35 years inclusive and in the overall study population. 
The general safety will be evaluated by the determination of routine laboratory parameters, 
vital signs, by performing physical, gynecological and breast examinations and by recording 
number, frequency, type and intensity of AEs and serious adverse events (SAEs).  
Participating subjects will be asked to record daily in a subject diary their bleeding/spotting 
episodes. This will allow evaluating the bleeding pattern and the cycle control associated with 
the investigational product. 
Treatment compliance will be assessed using data from the subject diary across the entire study 
and by cycle. The subject diary will also be used to determine whether or not a cycle is at risk 
for the Pearl Index calculation. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 24 of 114 
Physical, psychological and social functioning and well-being associated with the 
investigational product will be assessed with well-established questionnaires. A study schedule 
of events is provided in Appendix 1. Details and descriptions of study procedures are contained 
in the following sections. 
Population PK will be assessed using plasma E4 and DRSP concentration data from a subset 
of approximately 500 subjects to address the relationship between E4 and DRSP PK 
parameters and various individual characteristics (e.g., body weight, race, smoking, and 
fed/fasted condition). Blood samples for PK analysis will be obtained at Visits 3 and 4 between 
Days 10 and 14 of Cycles 2 and 4 (see Section 9.6.4.2). 
 
9.2 
Rationale for Study Design 
The design of this study is in line with the final minutes of the Advisory Committee for 
Reproductive Health Drugs meeting (FDA)3 held on January 23 and 24, 2007, the 
recommendations made by Kapp et al.4 and the requirements of the European Medicines 
Agency (EMA) and the EMEA/CPMP/EWP/519/98 Rev 1 Guideline on Clinical Investigation 
of Steroid Contraceptives in Women5 which states that: 
- 
Studies including an active comparator are not generally requested for efficacy 
purposes; 
- 
The duration of efficacy studies should be six months to one year or more;  
- 
For any new contraceptive, at least 400 women should have completed one year of 
treatment. 
This study is a multicenter, open-label, single-arm study which will allow quantification of the 
efficacy of the investigational product by calculating the pregnancy rate. The size of the study 
is also adequate to allow an assessment of the general safety and bleeding profile associated 
with the investigational product. 
The study design was discussed with FDA during end of phase 2 meeting as well as EMA 
during scientific advice (EMA/CHMP/SAWP/629721/2012). 
9.3 
Selection of Study Population 
This study will include healthy female subjects at risk for pregnancy, between 16 and 50 years 
old (inclusive) at the time of screening, and expressing the need for and desire to use 
contraception for at least 13 consecutive cycles.  
The following eligibility criteria will be checked at Visit 1 and Visit 2 (see Sections 9.5.1 and 
9.5.2). 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 25 of 114 
9.3.1 
Inclusion Criteria 
A subject will be considered for inclusion in the study if she meets all of the following criteria: 
1. Heterosexually active female at risk for pregnancy and requesting contraception. 
2. Negative serum pregnancy test at subject screening. 
3. Aged 16 to 50 years (inclusive) at the time of signing the informed consent (IC). 
4. Willing to use the investigational product as the primary method of contraception for 
13 consecutive cycles. 
5. Good physical and mental health on the basis of medical, surgical and gynecological 
history, physical examination, gynecological examination, clinical laboratory, and vital 
signs. 
6. Body mass index (BMI) below or equal to (≤) 35.0 kg/m2. 
7. Able to fulfill the requirements of the protocol and have indicated a willingness to 
participate in the study by providing written IC. 
8. Willing and able to complete the diaries and questionnaires. 
 
9.3.2 
Exclusion Criteria 
A subject will be excluded from participation if she meets any of the following criteria: 
1. For subjects who are not using hormonal contraception at screening, a menstrual cycle 
length shorter than 21 days or longer than 35 days.  
2. Clinically relevant abnormal laboratory result at screening in the opinion of the 
investigator with an understanding of the central laboratory normal range.  
3. Known hypersensitivity to any of the investigational product ingredients. 
4. Currently pregnant or with the intention to become pregnant during the course of the 
study. 
5. Currently breastfeeding or before two spontaneous menstruations have occurred after 
cessation of breastfeeding prior to start of trial medication. 
6. Less than 6 weeks since last delivery/2nd trimester of abortion and before spontaneous 
menstruation has occurred following a delivery or 2nd trimester of abortion. 
7. Smoking nicotine-containing products if ≥ 35 years old. 
8. Dyslipoproteinemia requiring active treatment with antilipidemic agent.  
9. Diabetes mellitus with vascular involvement (nephropathy, retinopathy, neuropathy, 
other) or diabetes mellitus of more than 20-year duration. 
10. Any arterial hypertension (controlled and uncontrolled) defined by blood pressure 
values of: 
a. systolic blood pressure ≥ 140 mmHg and/or,  
b. diastolic blood pressure ≥ 90 mmHg . 
11. Personal history of deep vein thrombosis or pulmonary embolism. 
12. Current prolonged immobilization or major surgery with prolonged immobilization 
planned in the next 12 months. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 26 of 114 
13. Known inherited or acquired hypercoagulopathies (e.g. antiphospholipid syndrome) or 
thrombogenic mutations (e.g. factor V Leiden, prothrombin mutation, protein S, 
protein C, and antithrombin deficiencies). 
14. Current treatment with anticoagulants. 
15. Presence or history of arterial thromboembolism (e.g. angina pectoris, ischemic heart 
disease, cerebral stroke or transient ischemic attack). 
16. Complicated valvular heart disease (pulmonary hypertension, atrial fibrillation, 
subacute bacterial endocarditis). 
17. History of pregnancy-related cardiomyopathy or moderately or severely impaired 
cardiac function. 
18. Systemic lupus erythematosus. 
19. Presence or history of migraine with aura at any age or migraine without aura if  35 
years old.  
20. Within the past 6 months, has had undiagnosed (unexplained) abnormal vaginal 
bleeding, or any abnormal bleeding that is expected to recur during the trial (e.g., 
bleeding from cervical polyp, recurrent bleeding after sex). 
21. In case of Chlamydial or gonococcal infection at screening, when no treatment initiated 
at subject enrollment. 
22. Abnormal Pap test (written documentation of prior test or test at screening exam) based 
on the following criteria: 
 Pap test in the past 18 months with ASC-US unless: 
o less than 21 years of age; or 
o a repeat Pap test at least 6 months later was normal; or 
o reflex HPV testing was performed and was negative for high-risk oncogene 
human-papilloma-virus (HPV). 
 Pap test in the past 18 months with LSIL unless less than 21 years of age. 
 Pap test in the past 18 months with ASC-H, atypical glandular cells, HSIL or 
malignant cells. 
23. Presence of an undiagnosed breast mass. 
24. Current symptomatic gallbladder disease. 
25. History of COC-related cholestasis. 
26. Presence or history of severe hepatic disease as long as liver function values have not 
returned to normal. 
27. Presence or history of pancreatitis if associated with hypertriglyceridemia.  
28. Porphyria. 
29. Presence or history of hepatocellular adenoma or malignant liver tumors. 
30. Renal impairment (GFR < 60 mL/min/1.73m²). 
31. Hyperkaliemia or presence of conditions that predispose to hyperkaliemia such as renal 
impairment, hepatic impairment, adrenal insufficiency and women receiving daily, 
long-term treatment for chronic conditions or diseases with medications that may 
increase serum potassium concentration (e.g. ACE inhibitors, angiotensin-II receptor 
antagonists, potassium-sparing diuretics, potassium supplementation, heparin, 
aldosterone antagonist and non-steroidal anti-inflammatory drugs). 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 27 of 114 
32. History of organ transplantation within 5 years before screening or chronic disease 
potentially necessitating organ transplantation during the anticipated course of the 
study. 
33. Presence or history of hormone-related malignancy. 
34. History of non-hormone-related malignancy within 5 years before screening. Subjects 
with a non-melanoma skin cancer are allowed in the study. 
35. Current regular use or regular use within 1 month prior to subject enrollment of drugs 
potentially triggering interactions with COCs including but not limited to: 
o Cytochrome P450 3A4 (CYP 3A4) inducers: barbiturates, primidone, bosentan, 
felbamate, griseofulvin, oxcarbazepine, topiramate, carbamazepine, phenytoin, 
rifampicin, St John’s wort. 
o CYP 3A4 inhibitors: azole antifungals, phenylbutazone, modafinil,   cimetidine, 
verapamil, macrolides, diltiazem and grapefruit juice. 
o Human immunodeficiency virus (HIV)/Hepatitis C virus (HCV) protease 
inhibitors and non-nucleoside reverse transcriptase inhibitors. 
36. Use of an injectable hormonal method of contraception within 10 months (300 days) 
prior to screening of an injection with a 3-month duration, within 6 months (180 days) 
prior to screening of an injection with a 2-month duration, within 3 months (90 days) 
prior to screening of an injection with a 1-month duration. 
37. History of alcohol or drug abuse (including laxatives) within 12 months prior to 
screening. 
38. Any prior procedure, disease or condition that could result in altered absorption, 
excessive accumulation, impaired metabolism, or altered excretion of the 
investigational product. 
39. Uncontrolled thyroid disorders. 
40. Participation in another investigational drug clinical study within 1 month (30 days) or 
have received an investigational drug within the last 3 months (90 days) prior to study 
entry. Subjects who participated in an oral contraceptive clinical study, using FDA/EU 
approved active ingredients, may be enrolled 2 months (60 days) after completing the 
preceding study.  
41. Sponsor, CRO or Investigator’s site personnel directly affiliated with this study. 
42. Is judged by the Investigator to be unsuitable for any reason. 
 
9.3.3 
Subject Identification 
Subject study identification numbers will be assigned at the Screening Visit. Subject numbers 
will be consecutive at each study site beginning with 001. Site numbering will begin at the 
number 201. Subject identification will consist of the site number (3 digits) followed by the 
subject number (3 digits), e.g., the first subject at Site 201 would be 201001 and the fifth 
subject at Site 235 would be 235005. Subject numbers will be consecutive at each study site 
beginning with 001. Subject identification numbers will be used throughout the trial. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 28 of 114 
9.4 
Study Treatment 
9.4.1 
Identity of Investigational Products 
The investigational products are manufactured by Haupt Pharma, Munster, Germany, in 
accordance with applicable current Good Manufacturing Practice (GMP). 
The following investigational products will be administered: 
Dosage form description 24 pink tablets containing 15 mg E4/3 mg DRSP  
4 white placebo tablets  
Package description 
Blister pack (PVC/Aluminum) containing 28 tablets (24 pink 
and 4 white tablets) 
Dose per time unit  
1 tablet daily 
Dispensing 
Dispense the blister as follows per subject: 
- 4 blisters on Visit 2 and then 3 blisters on Visits 4 (Cycle 4), 5 
(Cycle 7) and 6 (Cycle 10). 
- 1 spare blister on Visit 2 and, if necessary, on Visit 4, 5 and/or 
6. 
 
9.4.1.1 
Labeling 
The investigational product will be labeled according to regulations and local requirements 
and will contain at minimum the following information: 
 Drug name or number/code 
 Protocol number 
 Blister content (24 pink tablets containing 15 mg E4/3 mg DRSP and 4 white 
placebo tablets) 
 Lot number 
 Expiry date 
 For oral administration 
 Storage conditions 
 Caution: New Drug – Limited by Federal (or United States) law to investigational 
use. 
 Treatment number 
 Manufacturer’s name and address 
 Keep out of reach of children 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 29 of 114 
9.4.1.2 
Storage and Drug Accountability 
The Investigator will be responsible for the suitable storage of the investigational product in 
compliance with the storage instructions and must restrict access to the study personnel only. 
Under no circumstances will the Investigator allow the investigational products to be used 
other than as directed by this protocol.  The investigational product must be protected from 
unauthorized access (e.g. in a locked storage facility). Appropriate storage conditions at the 
site must be ensured either by controlled room temperature or by completion of a temperature 
log in accordance with local requirements and storage instructions on a regular basis, showing 
minimum and maximum temperatures reached over the time interval.  The Principal 
Investigator will have overall responsibility for the use of the investigational product at the 
site. The Principal Investigator or Designee will confirm receipt of the investigational product 
and will verify the contents of the shipment, using an interactive web response system (IWRS) 
upon receipt of the product. The Investigator or Designee shall maintain accurate 
investigational product inventory records, including the quantities and date of receipt of 
supplies from the Sponsor, and the quantities and dates of dispensing to each study subject. 
Shipping and handling of all investigational products will be conform to ICH-GCP guidelines, 
GMP and Local regulatory guidelines.    
At Visits 3, 4, 5, and 6, the Investigator should collect the investigational product (unused and 
empty) including spare blister if used (even if partially used) of the completed treatment cycles 
for drug accountability. Unused spare blister will be left for the subject. Used spare blisters 
will be replaced by a new spare blister. At Visit 7, the Investigator should collect all unused 
investigational product including spare blister (used or not), empty blisters for final drug 
accountability. 
At completion of the study, to satisfy regulatory requirements regarding drug accountability, 
all investigational products will be stored, inventoried, reconciled, and destroyed or returned 
to the Sponsor according to applicable regulations.  A written explanation must be provided 
for any discrepancies. The study monitor must review all records of drug accountability prior 
to the return or destruction of any supplies. 
This drug accountability log must be available for inspection during an audit (e.g., by Sponsor 
or a regulatory agency).  At the conclusion of the study, the Investigator must provide a copy 
of this record to the Sponsor. 
9.4.2 
Method of Assigning Subjects to Treatment 
This is a 1-treatment arm open-label study.  The subject will undergo screening where 
pretreatment clinical evaluations and specific procedures will be completed at the Screening 
Visit. Authorized site personnel will acknowledge that the subject met all of the specified 
inclusion criteria and none of the exclusion criteria before subject enrolment. 
At enrollment visit, after IWRS contact, investigational product packs labeled with study 
information will be assigned to the subject. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 30 of 114 
9.4.3 
Treatment Compliance 
Treatment compliance for the investigational product will be assessed based on the response 
values entered by the subject in the diary on a daily basis (see Section 9.6.1). A comparison 
will be made between the number of tablets expected to be used, based on the total number of 
treatment days, and the number of tablets taken according to the subject’s diary.  
In addition, the data will be used to identify when a pill has been missed.  
At each visit, the diary entries will be compared to the returned tablets to ensure consistency 
but the diary data will be used for compliance assessment. In case of discrepancy between the 
diary data and the returned tablets, the investigator will discuss with the subject and document 
this in the source data.  
9.4.4 
Selection of Doses and Timing of Administration in the Study 
The daily dose used in this study, i.e. 15 mg E4 and 3 mg DRSP, has been selected on the basis 
of the data generated during the Phase 2 program. It was associated with a high inhibition of 
ovarian function, no ovulation, a good safety profile, and the most favorable bleeding 
pattern/cycle control observed among the different E4 combinations that were evaluated (see 
Section 7.2). 
The investigational product is administered once daily following a 24/4-day regimen, i.e. one 
15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo 
tablet per day for 4 consecutive days.  
This 28-day cyclic regimen must be taken for up to 13 consecutive cycles. The treatment must 
be taken once daily at approximately the same time of the day. 
9.4.4.1 
Instructions for starting the first pack of tablets 
 Women who did not use any contraceptive method or who used a barrier 
contraceptive method will be instructed to begin the investigational product on the 
first day of the next menstrual bleeding. Starting on Days 2-5 is also allowed, but a 
condom must be used until the subject has completed 7 days of uninterrupted active 
tablet intake. If the menstrual cycle prior to start of first pack of tablets is shorter 
than 21 days or longer than 35 days, the subject should not start the investigational 
product and will be withdrawn from the study (section 13.4). The subject should 
contact the study staff as soon as possible to schedule an Early Termination Visit 
(section 9.5.4) and to discuss an alternative contraception to use (section 9.6.4.9).                          
 Women switching from another COC or progestin-only pill will start the 
investigational product at the time when the next pill pack of the previous pill would 
have been due. 
 Women switching from a hormonal vaginal ring or transdermal patch will start the 
investigational product when the next application would have been due. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 31 of 114 
 Women switching from an injectable hormonal method of contraception will start 
the investigational product on the first day of spontaneous menstrual bleeding 
following an interval after the last injection, which can vary depending of the form:  
 10 months after the injection of a product with a 3-month duration; 
 6 months after the injection of a product with a 2-month duration; 
 3 months after the injection of a product with a 1-month duration.  
Starting on Days 2-5 is also allowed, but a condom must be used until the subject 
has completed 7 days of uninterrupted active tablet intake.   
 Women switching from an intrauterine or dermally implantable contraceptive will 
start the investigational product on the day of removal. A condom must be used 
until the subject has completed 7 days of uninterrupted active tablet intake. 
The first day of the first pink tablet intake after enrollment is Day 1.  The subject places one 
of the 7 self-adhesive day label strips that corresponds to her Day 1 starting day onto the card 
of the blister to indicate the day she started. The study staff will show the subject how to fix 
the first label.  
She then starts taking one tablet daily, at approximately the same time of the day, beginning 
with the first pink tablet in the top row.  The subject completes her 28-tablet regimen when she 
has taken the last tablet in the blister pack.   
9.4.4.2 
Dosing Instructions 
Each time investigational product is dispensed to the subject, site personnel will instruct the 
subject as follows:  
 Take one pink tablet every day for 24 consecutive days (Day 1 through Day 24), 
followed by one white placebo tablet every day for 4 consecutive days (Day 25 
through Day 28). 
 When the pack of tablets is empty, start the next pack on the next day after the last 
white tablet of the previous pack has been taken. When starting a new pack of 
tablets, take the first pink tablet of the pack. There should be no interruption 
between two blister packs. 
 Take the investigational product at approximately the same time each day 
throughout the study.  The time of day should be determined by the subject.  
 Return all blister packs to site personnel at the following visit. 
 
9.4.4.3 
Instructions in case of missed tablet(s) or in conditions potentially 
reducing the contraceptive efficacy 
If the subject has vomiting or diarrhea within 4 hours of tablet intake, she should take 
another tablet from the extra pack (spare blister) as a replacement. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 32 of 114 
If the subject inadvertently misses one or more of the tablets, the following instructions 
must be followed6:   
 If one active pink tablet is late (< 24 hours since a tablet should have been 
taken) or if one active pink tablet has been missed (24 to < 48 hours since a 
tablet should have been taken):  
o Take the late or missed active pink tablet as soon as possible. 
o Continue taking the remaining active pink tablets at the usual time 
(even if it means taking two active pink tablets on the same day). 
o Use of condom is not required. 
 If two or more consecutive active pink tablets have been missed (≥ 48 hours 
since a tablet should have been taken): 
o If between Day 1 & Day 17: 
 Take the most recent missed active pink tablet as soon as 
possible (any other missed tablets should be discarded). 
 Continue taking the remaining active pink tablets at the usual 
time (even if it means taking two tablets on the same day). 
 Use condom or avoid sexual intercourse until 7 days of 
uninterrupted active pink tablet intake. 
 Consider emergency contraception as per current practice if 
the woman had unprotected intercourse during the missed 
pill interval. 
o If between Day 18 & Day 24:  
 Omit the hormone-free interval by finishing the active pink 
tablets in the current pack and starting a new pack the next 
day. 
 If unable to start a new pack immediately, use condoms or 
avoid sexual intercourse until 7 days of uninterrupted active 
pink tablet intake from the new pack. 
 If this occurs during the last cycle, the subject should contact 
the study staff to know what she has to do with the next 
contraception. 
If the subject inadvertently misses any of the white placebo tablets: 
 Skip the missed white placebo tablet(s) and the remaining tablets are taken 
at the regular time.  
 Use of condoms is not required during this time.   

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 33 of 114 
Anytime a subsequent cycle of the product/pack is started later than the day following 
administration of the last white tablet, the subject should use condoms until she has taken pink 
tablets daily for 7 consecutive days. 
 
9.4.4.4 
In case of short-term intake of drugs that may decrease the efficacy of 
the COC  
Subject is allowed to take drugs potentially decreasing the efficacy of the COC for a maximal 
period of 10 consecutive days (for example, CYP 3A4 inducers). Subjects must be instructed 
to use condoms when these drugs are used and during 7 days of uninterrupted pink tablet intake 
after finishing the medication. 
 
9.4.4.5 
Use of the investigational product in case of bleeding/spotting episode 
Scheduled bleeding is expected to begin within a few days of taking the last active tablet (i.e. 
pink tablet), but may begin sooner or later. If spotting occurs while on the usual regimen of 
one tablet daily, the subject should continue medication without interruption.  She should be 
instructed that this type of bleeding is often transient and without significance.  However, if 
the bleeding is persistent or prolonged, nonfunctional causes may be considered and the subject 
should be advised to call the Investigator who will decide the best management for the subject. 
The bleeding profile will be recorded by the subject on a subject diary.  
9.4.4.6 
Use of the investigational product in the event of a missed menstrual 
period 
A missed menstrual period may occur even if the subject adhered to the prescribed dosage 
regimen. However, as the contraceptive method used in this study is still under investigation, 
a rapid detection of any pregnancy is necessary. For this reason, if the subject presents a missed 
period, she will be instructed to use the home urine pregnancy test provided by the study staff 
to rule out pregnancy before continuing the contraceptive regimen (see Section 9.6.2).   
9.4.5 
Blinding 
This is an open-label study. 
9.4.6 
Restrictions 
9.4.6.1 
Prior and Concomitant Therapy 
Medications with an end date occurring before the first investigational product dose date in the 
treatment period will be identified as prior medications. Medications with a start date occurring 
on or after the first investigational product dose date in the treatment period or medications 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 34 of 114 
with a start date prior to the first investigational product dose date and an end date on or after 
the first investigational product dose date will be identified as concomitant medications. 
Unauthorized Prior Therapies: 
 Use of an injectable hormonal method of contraception within 10 months (300 
days) prior to screening for an injection with a 3-month duration, within 6 months 
(180 days) prior to screening for an injection with a 2-month duration, within 3 
months (90 days) prior to screening for an injection with a 1-month duration. 
 Use of drugs potentially triggering interactions with COC within one month prior 
to subjects’ enrollment. This includes, but is not limited to: 
o CYP 3A4 inducers: barbiturates, primidone, bosentan, felbamate, griseofulvin, 
oxcarbazepine, topiramate, carbamazepine, phenytoin, rifampicin, St John’s 
wort. 
o CYP 3A4 inhibitors: azole antifungals, phenylbutazone, modafinil, cimetidine, 
verapamil, macrolides, diltiazem and grapefruit juice. 
o HIV/HCV protease inhibitors and non-nucleoside reverse transcriptase 
inhibitors. 
Unauthorized Concomitant Therapies: 
 Use of any contraceptive method other than the investigational product.  
Note: use of condoms is only allowed during the course of the study to avoid 
transmission of sexually transmitted infections (STIs), or in case of missed tablets, 
or when unauthorized concomitant therapies are used. Condom use must be 
recorded in the subject diary.  
 Daily, long-term treatment for chronic conditions or diseases with medications that 
may increase serum potassium concentration (e.g. ACE inhibitors, angiotensin-II 
receptor antagonists, potassium-sparing diuretics, potassium supplementation, 
heparin, aldosterone antagonist and non-steroidal anti-inflammatory drugs). 
 Use of drugs potentially triggering interactions with COC. This includes, but is not 
limited to: 
o CYP 3A4 inducers: barbiturates, primidone, bosentan, felbamate, griseofulvin, 
oxcarbazepine, topiramate, carbamazepine, phenytoin, rifampicin, St John’s 
wort.  
o CYP 3A4 inhibitors: azole antifungals, phenylbutazone, modafinil,   cimetidine, 
verapamil, macrolides, diltiazem and grapefruit juice. 
o HIV/HCV protease inhibitors and non-nucleoside reverse transcriptase 
inhibitors. 
These drugs or herbal products may decrease the effectiveness of hormonal 
contraceptives or increase breakthrough bleeding. Subjects must be instructed 
to use a back-up contraceptive method when these drugs are used, up to and 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 35 of 114 
including the next 7 days after finishing the concomitant therapy and to record 
this back-up contraception in the subject diary (see Section 9.6.1). It is the 
responsibility of the Investigator to ensure that any change in concomitant 
medications during the study is recorded in the source documentation and 
entered in the electronic case report form (eCRF). 
Warning: oral contraceptives may interfere with the metabolism of other drugs. Accordingly, 
plasma and tissue concentrations may be affected (e.g. cyclosporine). Consult the prescribing 
information of concomitant drugs for possible interactions with oral contraceptives. 
9.4.6.2 
Condoms and other contraceptive methods 
Use of condoms is allowed during the course of the study only to avoid transmission of STIs 
or in case of missed tablet(s) or unauthorized concomitant therapies. Condom use must be 
recorded in the subject diary. Use of any other contraceptive methods must also be recorded in 
the subject diary (see Section 9.6.1). The cycles during which condom(s) or other contraceptive 
method(s) than the investigational product were used will be excluded from the Pearl Index 
calculation. 
9.4.7 
Treatment beyond the clinical trial 
Post-treatment contraceptive counseling should be given to each subject at Visit 6 and at the 
Early Termination Visit in case of premature study termination. Post-treatment contraceptive 
treatment should be started no later than on the day following the last tablet intake of the trial 
medication. 
9.5 
Study Activities 
The following sections provide details of the study activities which are summarized in the 
Schedule of Events (Appendix 1). The study will include 1 Screening Visit (Visit 1), 1 
enrollment Visit (Visit 2), 4 in-treatment Visits (Visits 3 to 6) and 1 exit Visit (Visit 7). 
At any time during the study, an Unscheduled Visit may occur in case of suspicion of 
pregnancy. 
9.5.1 
Visit 1: Screening Visit  
The subject must be fasting for at least 8 hours (overnight fast) before the Screening Visit. 
Prior to conducting any screening procedures, subjects will be given a full description of the 
nature of the study. The purpose, timing, procedures, and risks of the study will be explained 
to the subject, including requirements for enrollment and participation in the study, medication 
restrictions during the study, and requirements for washout of certain medications that the 
subject may already be taking. The eligible subject who is willing to participate in the study 
will then be required to provide written consent. The Investigator or a designated medically 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 36 of 114 
qualified member of the study staff will interview potential participants to establish their 
eligibility for inclusion in the study.   
Potential subjects will be screened according to the inclusion and exclusion criteria within 45 
days prior to the subject enrollment visit (Visit 2). Subjects who were eligible for the study but 
did not enroll within 45 days of screening (Visit 1) can be re-screened. Re-screening requires 
all Visit 1 assessments to be repeated. The Investigator will maintain a log of all subjects 
screened for participation and record the reason(s) for excluding potential subjects. 
The following will be performed to determine eligibility: 
1. Obtain signed IC from subjects. Subjects will receive a copy of the IC (see Section 
10.3); 
2. Review and document inclusion and exclusion criteria (see Sections 9.3.1 and 9.3.2); 
3. Record demographic information (see Section 9.6.4.4); 
4. Obtain medical and surgical history (see Section 9.6.4.6); 
5. Obtain gynecological history including identification of the previous contraceptive 
method used, if any (see Section 9.6.4.7); 
6. Obtain prior medication use information (see Section 9.6.4.5); 
7. Perform a physical examination (see Section 9.6.3.4); 
8. Perform a gynecological examination including breast examination (see Section 
9.6.3.6); 
9. Obtain cervical cytology (see Section 9.6.3.6); 
10. Perform a Chlamydia test (see Section 9.6.3.6); 
11. Perform a gonorrhea test (see Section 9.6.3.6); 
12. Collect fasting (8-hour) blood samples for hematology, biochemistry and pregnancy 
test (see Sections 9.6.2.1 and 9.6.3.3); 
13. Measure vital signs (see Section 9.6.3.7); 
14. Measure height and weight, and calculate BMI (see Section 9.6.3.5); 
15. Schedule the next study visit. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 37 of 114 
9.5.2 
Visit 2: Subject Enrollment 
The Visit 2 will occur within 45 days after the Screening Visit (Visit 1), when the entire 
laboratory results of the subject have been received. 
On the basis of the laboratory results, the Investigator must assess the eligibility of the subject.  
In case of positive Chlamydia or gonorrhea test result (see Section 9.6.3.6), the subject will be 
treated before enrollment. Choice of treatment is left at the Investigator’s discretion. 
During Visit 2, the following procedures will be performed: 
1. Review, confirm and document inclusion and exclusion criteria (see Sections 9.3.1 and 
9.3.2); 
2. Obtain prior medication use information (see Section 9.6.4.5 and Section 9.4.6 for 
restrictions); 
3. If all screening assessments are acceptable and all inclusion criteria and no exclusion 
criteria have been met, the subject will be enrolled in the study;  
4. Perform a Chlamydia and gonorrhea test, if indicated (see Section 9.6.3.6); 
5. Measure vital signs (see Section 9.6.3.7); 
6. Dispense investigational products for Cycle 1-4 and one spare blister pack and give the 
subject the instructions for use (see Section 9.4.4.2); 
7. Dispense subject diary and give the subject the instructions for use (see Section 9.6.1); 
8. Dispense home urine pregnancy test kits with the instructions for use. Subject should 
perform a urinary pregnancy test just before the intake of the first pink tablet, preferably 
with first urine in the morning. The result has to be recorded in the diary. The subject 
should only start with the trial medication when the pregnancy test is negative (not 
pregnant). If the pregnancy test is positive, the subject should not take any trial 
medication and contact the Investigator. The Investigator should arrange for an 
Unscheduled Visit (see Section 9.5.5) to confirm the pregnancy, complete the 
Pregnancy Report Form if the pregnancy is confirmed (see Section 9.6.2.1) and the 
subject should be withdrawn; 
9. Query the subject as to the occurrence of any AE(s) and record any AE(s) observed or 
spontaneously volunteered by the subject (see Section 9.6.3.1); 
10. Dispense the questionnaires and give the subject the instructions for completion (see 
Section 9.6.4.11); 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 38 of 114 
11. Schedule or confirm the next study visit and the follow-up phone call; 
12. Instruct the subject to come to the next visit with her subject diary and the unused 
investigational product, including empty blisters, spare and boxes; 
13. Instruct any subject not on a hormonal contraceptive and who does not start the 
investigational product at the enrollment visit to contact the site immediately if her next 
menses occurs at earlier than 21 days or is delayed such that her cycle length exceeds 
35 days, and that she should not start the investigational product if either of these 
happens; 
14. Instruct the subject to contact the site immediately if she decides to discontinue the 
investigational product and, if possible, to not discontinue the investigational product 
before contacting the site; 
15. Complete a follow-up call within 7 days following the expected start date of the 
treatment to remind the subject to complete the diary entries. 
9.5.3 
Treatment Period (from Cycle 1 Day 1 until Cycle 13 Day 28) 
9.5.3.1 
Visit 3 (Cycle 2, between Day 1 and Day 14) 
The following procedures will be performed: 
1. Perform a Chlamydia and gonorrhea test, if indicated (see Section 9.6.3.6); 
2. Measure vital signs (see Section 9.6.3.7); 
3. Query the stop date of the previous contraceptive method; 
4. Investigational product return and drug accountability (see Section 9.4.1.2); 
5. Collect and review completed subject diary pages and return the diary to the subject 
(see Section 9.6.1); 
6. Ensure appropriate completion of the questionnaires; 
7. Collect blood samples from the subjects participating in the Population PK Substudy 
according to the sampling scheme outlined in Section 9.6.4.2. Note that Visit 3 for the 
subjects in the Population PK Substudy should be performed between Days 10 and 14; 
8. Query the subject as to the occurrence of any TEAE(s) and record any TEAE(s) 
observed or spontaneously volunteered by the subject (see Section 9.6.3.1); 
9. Obtain concomitant medication use (see Section 9.6.4.5 and Section 9.4.6 for 
restrictions); 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 39 of 114 
10. Schedule or confirm the next study visit; 
11. Instruct the subject to come to the next visit with her subject diary and the unused 
investigational product, including empty blisters, spare and boxes; 
12. Instruct the subject to contact the site immediately if she decides to discontinue the 
investigational product and, if possible, to not discontinue the investigational product 
before contacting the site. 
9.5.3.2 
Visit 4 (Cycle 4, between Day 1 and 14) 
The following procedures will be performed: 
1. Perform a Chlamydia and gonorrhea test, if indicated (see Section 9.6.3.6); 
2. Measure vital signs (see Section 9.6.3.7); 
3. Measure weight and calculate BMI (see Section 9.6.3.5); 
4. Collect blood samples from the subjects participating in the Population PK Substudy 
according to the sampling scheme outlined in Section 9.6.4.2. Note that Visit 4 for the 
subjects in the Population PK Substudy should be performed between Days 10 and 14; 
5. Investigational product return and drug accountability (see Section 9.4.1.2); 
6. Dispense investigational products for the next 3 cycles and remind the subject the 
instructions for use (see Section 9.4.4.2); 
7. Collect and review completed subject diary pages and return the diary to the subject 
(see Section 9.6.1); 
8. Query the subject as to the occurrence of any TEAE(s) and record any TEAE(s) 
observed or spontaneously volunteered by the subject (see Section 9.6.3.1); 
9. Obtain concomitant medication use (see Section 9.6.4.5 and Section 9.4.6 for 
restrictions); 
10. Schedule or confirm the next study visit; 
11. Instruct the subject to come to the next visit in a fasted state, with her subject diary 
and the unused investigational products, including empty blisters, spare and boxes; 
12. Instruct the subject to contact the site immediately if she decides to discontinue the 
investigational product and, if possible, to not discontinue the investigational product 
before contacting the site. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 40 of 114 
9.5.3.3 
Visit 5 (Cycle 7, between Day 1 and 14) 
The following procedures will be performed: 
1. Perform a Chlamydia and gonorrhea test, if indicated (see Section 9.6.3.6); 
2. Measure vital signs (see Section 9.6.3.7); 
3. Measure weight and calculate BMI (see Section 9.6.3.5); 
4. Investigational product return and drug accountability (see Section 9.4.1.2); 
5. Dispense investigational products for the next 3 cycles and remind the subject the 
instructions for use (see Section 9.4.4.2); 
6. Collect and review completed subject diary pages and return the diary to the subject 
(see Section 9.6.1); 
7. Query the subject as to the occurrence of any TEAE(s) and record any TEAE(s) 
observed or spontaneously volunteered by the subject (see Section 9.6.3.1); 
8. Obtain concomitant medication use (see Section 9.6.4.5 and Section 9.4.6 for 
restrictions); 
9. Collect fasting (8-hour) blood samples for biochemistry (see Sections 9.6.3.3); 
10. Schedule or confirm the next study visit; 
11. Instruct the subject to come to the next visit with her subject diary and the unused 
investigational products, including empty blisters, spare and boxes; 
12. Instruct the subject to contact the site immediately if she decides to discontinue the 
investigational product and, if possible, to not discontinue the investigational product 
before contacting the site. 
9.5.3.4 
Visit 6 (Cycle 10, between Day 1 and 14) 
The following procedures will be performed: 
1. Perform a Chlamydia and gonorrhea test, if indicated (see Section 9.6.3.6); 
2. Measure vital signs (see Section 9.6.3.7); 
3. Investigational product return and drug accountability (see Section 9.4.1.2); 
4. Dispense investigational products for the next 3 cycles and remind the subject the 
instructions for use (see Section 9.4.4.2); 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 41 of 114 
5. Collect and review completed subject diary pages and return the diary to the subject 
(see Section 9.6.1); 
6. Dispense the questionnaires and give the subject the instructions for completion 
(see Section 9.6.4.11); 
7. Query the subject as to the occurrence of any TEAE(s) and record any TEAE(s) 
observed or spontaneously volunteered by the subject (see Section 9.6.3.1); 
8. Obtain concomitant medication use (see Section 9.6.4.5 and Section 9.4.6 for 
restrictions); 
9. Give the subject counseling about the next contraceptive method to use at the end 
of the study (see Section 9.6.4.9); 
10. On the day the subject is expected to start the next contraceptive method (±1 day), 
perform a follow-up call to ensure subject’s compliance with this method (see 
Section 9.6.4.9). 
11. Schedule or confirm the next study visit; 
12. Instruct the subject to come to the next visit in a fasted state with her subject diary 
and the unused investigational products, including empty blisters, spare and boxes; 
13. Instruct the subject to contact the site immediately if she decides to discontinue the 
investigational product and, if possible, to not discontinue the investigational 
product before contacting the site. 
9.5.3.5 
Visit 7 (Cycle 14, between Day 16 and 23), End of Treatment Visit 
The following procedures will be performed: 
1. Perform a physical examination (see Section 9.6.3.4); 
2. Measure weight and calculate BMI (see Section 9.6.3.5); 
3. Perform a gynecological examination including breast examination (see Section 
9.6.3.6);  
4. Collect fasting (8-hour) blood samples for hematology, biochemistry and pregnancy 
test (see Sections 9.6.2.1 and 9.6.3.3); 
5. Measure vital signs (see Section 9.6.3.7); 
6. Investigational product return and drug accountability (see Section 9.4.1.2); 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 42 of 114 
7. Collect and review completed subject diary pages (see Section 9.6.1); 
8. Ensure appropriate completion of the questionnaires; 
9. Query the subject as to the occurrence of any TEAE(s) and record any TEAE(s) 
observed or spontaneously volunteered by the subject (see Section 9.6.3.1); 
10. Obtain concomitant medication use (see Section 9.6.4.5 and Section 9.4.6 for 
restrictions); 
11. Complete the End of Study Form. 
9.5.4 
Early Termination Visit  
A subject who desires early termination or is withdrawn from the study after the enrollment 
visit (Visit 2) (section 13.4) will require an Early Termination Visit. 
 Any subject who contacts the study site with a desire to discontinue study participation 
should be instructed at each visit to contact the study staff before discontinuing the 
study drug to be counseled about alternative contraception to use prior to the Early 
Termination Visit (see Section 9.6.4.9). Study sites may provide any prescription or 
non-prescription contraceptive to the subject as is medically appropriate per local 
standard of care other than an IUD or implant. If necessary, an unscheduled visit can 
occur to provide contraception (see Section 9.5.5). 
 A subject who presents to the study site for a scheduled visit and desires to discontinue 
study participation or is withdrawn from the study at that visit should be counseled 
about alternative contraception to use prior to the Early Termination Visit (see Section 
9.6.4.9). Study sites may provide any prescription or non-prescription contraceptive to 
the subject as is medically appropriate per local standard of care other than an IUD or 
implant. 
 A subject who presents to the study site for a scheduled visit who has not taken the 
study product for 16 days or more should have the scheduled visit procedures and the 
Early Termination Visit procedures completed at that time. The subject should be 
counseled about alternative contraception (see Section 9.6.4.9). Study sites may 
provide any prescription or non-prescription contraceptive to the subject as is medically 
appropriate per local standard of care. 
The Early Termination Visit should occur between 16 and 23 days after the last investigational 
product intake or immediately if the investigational product was never started. The procedures 
listed in Visit 7 (see Section 9.5.3.5) will be performed and the End of Study Form will be 
completed.  
Study site personnel will attempt to follow the progress of every subject admitted to the study 
through to study completion. If a subject fails to return for a scheduled visit, a reasonable effort 
should be made to contact the subject and ascertain the reason(s) for not returning. As a 
minimum, the site staff will contact the subject twice by phone and, if no response, will send 
a letter by registered mail. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 43 of 114 
If a subject does not complete the study for any reason (including Investigator discretion), the 
reason and circumstances for the subject’s early termination must be fully documented.   
The Sponsor or Designee must be informed in a timely manner if any subject withdraws from 
the study, regardless of the cause. Withdrawn subjects may not be re-enrolled in the study and 
will not be replaced. 
9.5.5 
Unscheduled Visit 
At any time of the study, an Unscheduled Visit could occur in case of suspicion of pregnancy 
based on a positive pregnancy test performed at home by the subject, in case the Investigator 
judges it necessary to examine a subject who would present a potential significant adverse 
event in the Investigator’s opinion, or if alternative contraception is needed for a subject 
planning early termination. Additional assessments can be performed at the Investigator’s 
discretion. 
9.6 
Study Variables and Procedure Descriptions 
9.6.1 
Subject Diary 
Subject diaries will be given to the participating subjects at Visit 2. Subjects will be instructed 
on how to complete it by the Investigator or Designee.  
The following information is to be recorded in the subject diary: 
- 
Date of the intake of the first tablet at each cycle; 
- 
Tablet intake on a daily basis; 
- 
Absence or occurrence of vaginal bleeding/spotting event(s) on a daily basis: 
 0 = Absence of vaginal bleeding or spotting; 
 1 = Spotting: evidence of minimal vaginal blood loss that does not 
require new use of sanitary protection, including pantyliners; 
 2 = Bleeding: evidence of vaginal blood loss that requires the use of 
sanitary protection with a tampon, pad or pantyliner; 
- 
Use of contraceptive method other than the investigational product (e.g. condom) 
during the cycle;  
- 
Occurrence of heterosexual intercourse during the cycle; 
- 
Result of the urine pregnancy test(s) performed at home (at cycle 1 before the first pill 
intake and at subsequent cycles in case of absence of menstruation). 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 44 of 114 
At Visits 3, 4, 5, 6 and 7, the completed pages of the subject diary will be collected and 
reviewed by the Investigator. At Visits 3, 4, 5, and 6 the subject diary will be returned to the 
subject for further completion. At Visit 7, the fully completed last pages of the subject diary 
will be returned by the subject. 
9.6.2 
Efficacy Assessments 
Contraceptive efficacy will be based on the Pearl Index, the method failure Pearl Index and the 
cumulative pregnancy rate.  
On-treatment pregnancies are defined as pregnancies with an estimated date of conception 
within the in-treatment period (Day 1 to 7 days after the intake of investigational product, 
whether active or inactive tablet). 
Pre-treatment pregnancies are pregnancies with an estimated date of conception before the first 
intake of trial medication. 
Post-treatment pregnancies are pregnancies with an estimated date of conception after the in-
treatment period (> 7 days after the intake of investigational product, whether active or inactive 
tablet). 
9.6.2.1 
Pregnancy Testing and Estimating Date of Conception 
The occurrence of pregnancies will be evaluated during the study by performing: 
- 
At Screening Visit (Visit 1) and Visit 7: a serum pregnancy test; 
- 
Just before intake of the first study medication and in case of missing menstrual period, 
the subject will perform a urine pregnancy test at home. For that purpose, home 
pregnancy kits will be provided to all subjects at Visit 2 and the subjects will be 
instructed on how to use it. In case of positive urine pregnancy test result, the subject 
will be instructed to contact the study staff immediately and the subject will be 
instructed not to take the investigational product. An appointment will be scheduled 
with the study staff for the pregnancy follow-up as soon as possible. The subject will 
be asked to record in the subject diary (see Section 9.6.1) the result of the urine 
pregnancy test performed at home; 
At any time: the subject is asked to contact immediately the study staff in the event of a 
suspected pregnancy. An appointment will be scheduled with the study staff for the pregnancy 
confirmation as soon as possible. The Investigator and or Designee will make every effort to 
see the subject as soon as possible to perform a serum pregnancy test.   
All subjects for whom a pregnancy is suspected due to a positive serum pregnancy test will be 
carefully evaluated and assessed to determine the estimated date of conception.  The preferred 
method is to perform an ultrasound to define the estimated age of the pregnancy; the estimated 
date of conception will then be calculated from this result.  In addition, information about all 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 45 of 114 
pregnancy tests, about bleeding and study drug intake (which must be reconciled with subject 
diary data), information about concomitant medications (which must be reconciled with 
information in the eCRF) will be obtained.  The Sponsor and Site Monitor must be notified 
and available information captured.  All information must be documented using the Pregnancy 
Report Form.  
Information pertaining to the reporting of pregnancy should be captured on the Pregnancy 
Report Form. This form will be used for initial and follow-up reporting. The form should be 
completed and returned to the PRA Safety team. The subject will be followed until the outcome 
of pregnancy is known.   
9.6.2.2 
Pregnancy Reporting 
Pregnancy will not be considered an AE but, because of its importance, information about each 
pregnancy should be treated in an urgent manner.  The Sponsor or Designee must be notified 
within 24 hours of the suspected diagnosis and all follow-up information should be obtained 
promptly. 
If during the course of the study, a subject is found to be pregnant, the investigational product 
will be discontinued and study participation terminated.  
The site will submit a Pregnancy Report Form to the Safety Monitor. 
The following contact will be used for all communications with the Safety Monitor/Drug 
Safety of this study: 
PRA Safety & Risk Management 
Fax: +1 (888) 772-6919 
Email: CHOSafety@prahs.com 
All pregnancies identified during the course of the study in a subject who was using the 
investigational product will be monitored to completion, i.e., approximately 9 month follow-
up in the case of live birth or until outcome information is obtained. Information will also be 
collected on any maternal or fetal complications. Miscarriage and any congenital abnormalities 
or birth defects will be classified as SAEs. Pregnancy outcome information will be recorded 
on specific forms and the data will be analyzed within the drug safety assessment.  Every 
attempt should be made to obtain outcome data including hospital or medical records.  
If a subject becomes pregnant and states she never started the investigational product, the 
pregnancy does not have to be monitored if the subject returns all of the investigational product 
(proving she never started the investigational product). 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 46 of 114 
9.6.3 
Safety Variables 
Safety evaluations will include the following: 
 General safety will be assessed in terms of occurrence of AEs/SAEs;  
 Extent of exposure 
 Clinical laboratory evaluations 
 Physical examination 
 Gynecological examination  
 Vital signs 
9.6.3.1 
Adverse Events 
AEs will be assessed from the time of signing the IC until exit from the study.  At every study 
visit from Visit 2, subjects will be asked an indirect standard question to elicit any medically 
related changes in their well-being.  They will also be asked if they have been hospitalized, 
had any accidents, used any new medications, or changed any current medication regimens 
(both prescription and over-the-counter medications). 
Definition of Terms 
Adverse Event (AE):  Any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related. In addition to novel events, an AE may be an 
exacerbation of a pre-existing medical condition that was present before the subject was 
assigned to a treatment group.  Each AE is described using all three of the following 
classifications: expected or unexpected; related or unrelated; and serious or non-serious.  
Additionally, intensity of the event is also described. 
Treatment-emergent adverse event (TEAE): A TEAE is any AE not present prior to the 
initiation of the treatments or any event already present that worsens in either intensity or 
frequency following exposure to the treatment. Since the starting point for AEs collection is 
the signing of the IC, not the start of the study treatment, the AEs recorded prior to first 
investigational product administration are designated as AEs while those that occur or worsen 
after the initiation of the investigational product are designated as TEAEs.   
Exacerbation of Pre-Existing Medical Condition:  An increase in the frequency or severity 
of a medical condition that is present before first investigational product administration.  Any 
medical condition that is present before first investigational product administration and that 
does not deteriorate should not be reported as an AE. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 47 of 114 
Expected: The determination of whether an AE is expected is based on previous experience 
with the investigational product, as follows: 
Expected AEs are AEs that have already been identified during the investigational product’s 
use, or are a known complication of standard medical procedures that may be conducted as 
part of the clinical study. 
Expected AEs are defined as those described in the Investigator’s Brochure (IB).  If an event 
increases in intensity or severity from that described in the IB, it will be considered unexpected. 
Unexpected AEs are all other AEs which are not deemed anticipated.  Note that anticipated 
AEs which are more severe must also be considered unanticipated AEs. 
Severity: The severity of each AE should be recorded as mild, moderate, or severe according 
to the following definition: 
Mild – transient and well-tolerated by the study subject, 
Moderate – causes discomfort and a temporary interference with daily living, 
Severe – substantially interferes with daily living to the point of being incapacitating and/or 
life threatening. 
Adverse Event Causality: 
The Investigator will evaluate the relationship of each AE to study drug and/or study 
procedures according to the following definitions:  
 
Category Criteria 
Final Reporting of Relationship to 
Study Drug 
Highly 
probable 
-Event 
or 
laboratory 
test 
abnormality, with plausible time 
relationship to drug intake. 
-Cannot be explained by disease or 
other drugs. 
-Response to withdrawal plausible 
(pharmacologically, 
pathologically). 
Related 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 48 of 114 
Category Criteria 
Final Reporting of Relationship to 
Study Drug 
-Event pharmacologically and/or 
phenomenologically related. 
-Rechallenge 
satisfactory, 
if 
necessary. 
Probable 
-Event 
or 
laboratory 
test 
abnormality, with reasonable time 
relationship to investigational drug 
intake. 
-Unlikely to be attributed to 
disease or other drugs. 
-Response to withdrawal clinically 
reasonable. 
-Rechallenge not required. 
Possible 
-Event 
or 
laboratory 
test 
abnormality, with reasonable time 
relationship to investigational drug 
intake. 
-Could also be explained by 
disease or other drugs. 
-Information on drug withdrawal 
may be lacking or unclear. 
Unlikely 
-Event 
or 
laboratory 
test 
abnormality, with a time to 
investigational product intake that 
makes a relationship improbable 
(but not impossible). 
-Disease or other drugs provide 
plausible explanations. 
Not Related 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 49 of 114 
Category Criteria 
Final Reporting of Relationship to 
Study Drug 
Not 
Related 
Event 
due to 
underlying or 
concurrent illness, complications, 
concurrent treatments or effect of 
another concurrent drug/therapy 
and is not associated to the 
investigational drug. 
 
Serious:  An AE is considered “serious” if, in the view of either the Investigator or Sponsor, 
it results in any of the following outcomes:  
• Death: the AE causes or contributes to the death.  Death is usually considered to be the 
outcome of an event; the event that leads to death is defined as the SAE. 
• A life-threatening adverse event: if, in the view of the Investigator or Sponsor, its 
occurrence places the subject at immediate risk of death. It does not include an AE that, 
had it occurred in a more severe form, might have caused death. 
• Inpatient hospitalization or prolongation of existing hospitalization: the AE requires at least 
a 24-hour inpatient hospitalization or prolongs a hospitalization beyond the expected length 
of stay. Hospital admissions for surgery planned before study entry, for social reasons or 
for normal disease management procedures are not to be considered SAE according to this 
criterion.  Where the protocol or the standard management of the disease under study 
requires planned hospitalizations for disease or treatment management, this should not be 
considered a serious criterion leading to expedited reporting. 
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions. 
• Congenital anomaly/birth defect: an adverse outcome in a child or fetus of a patient 
exposed to the investigational product before conception or during pregnancy. 
• Important medical event: such an event may not result in death, be life-threatening, or 
require hospitalization but may be considered serious when, based upon appropriate 
medical judgment; it may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse. 
 
For the purpose of this study, all events that meet the regulatory definition of an SAE that occur 
at any time during the study will be reported to the Sponsor as SAEs. Any SAE requires 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 50 of 114 
expedited reporting to Sponsor regardless of its relationship to the investigational product. 
Non-SAEs are all other AEs not deemed serious. 
Investigator Obligations 
Assessing and Following:  The Investigator is responsible for assessing all AEs that occur at 
any time during the study. The Investigator must make a determination of relatedness, 
seriousness, and intensity on the Adverse Events page of the eCRF for each AE.  All AEs must 
be followed to adequate resolution or stabilization.  If the AE has not resolved or stabilized by 
the time the subject completes the final study visit, the Investigator will follow the status of 
the subject's AE for at least 30 days beyond the subject's final study visit, unless directed 
otherwise by the Sponsor. 
Documenting:  All AEs during the study will be documented in the subject’s medical record.  
This information will then be transcribed on the AEs page of the eCRF by designated study 
personnel.  Required information includes a description of the event, date of onset, date of 
resolution, if death occurred, the action taken to manage the AE, as well as relatedness, 
seriousness, and intensity. 
AE information must be recorded regardless of its relatedness to the use of the investigational 
product.  AEs resulting from concurrent illnesses, reactions to concurrent medications, or 
progression of disease states must also be reported. 
Reporting:  1) The Investigator is responsible for reporting AEs to the Institutional Review 
Board (IRB) according to agreements and instructions from that committee that oversees this 
research, as well as according to applicable regulations. 2) Additionally, all AEs will be 
reported to the Sponsor or Designee on the eCRF, and all SAEs, whether expected or 
unexpected, related or unrelated, must be reported to PRA Drug Safety , by 24/7 e-mail or 
facsimile using the “Serious Adverse Event Report” form provided by the Sponsor or 
Designee, within 24 hours after the Investigator first learns of the event   In addition to the 
form, the following completed eCRF pages containing relevant information must also be 
faxed/mailed to the PRA Drug Safety: Medical History and Current Medications. The 
Investigator is responsible for reporting any new or relevant follow-up information on the 
SAEs within 24 hours after the investigator learns of the new information.  The Investigator 
should cooperate and furnish additional information, including copies of pertinent records if 
necessary, to assist the safety team in their evaluation of the event. 
Medical Emergencies and Emergency Protocol Deviations 
In medical emergencies, the Investigator will use medical judgment and remove the subject 
from immediate harm.  The Investigator will then immediately notify the Safety Monitor and 
the IRB regarding the type of emergency and the course of action taken. 
An investigator shall notify the Safety Monitor and the reviewing IRB of any deviation from 
the investigational plan to protect the life or physical well-being of a subject in an emergency.  

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 51 of 114 
Such notice shall be given as soon as possible, but in no event later than 5 working days after 
the emergency occurred.  Except in such an emergency, prior approval by the Safety Monitor 
is required for any changes in or deviations from the protocol.  All deviations must be 
documented on the eCRF. 
The following contact will be used for all communications with the Safety Monitor/Drug 
Safety of this study: 
PRA Safety & Risk Management 
Fax: +1 (888) 772-6919 
Email: CHOSafety@prahs.com 
Sponsor Reporting Obligations 
Sponsor or Designee will forward all reportable AEs to the appropriate regulatory authorities, 
ECs, and participating Investigators according to 21 Code of Federal Regulations (CFR) 312, 
and any other applicable regulations. 
9.6.3.2 
Extent of Exposure 
The extent of exposure to the investigational product will be determined from the first and last 
dosing dates during the treatment period and is derived as the last dose date – the first dose 
date + 1.  
9.6.3.3 
Clinical Laboratory Evaluations 
Methods for blood sample collection, processing, and shipment are described in instructional 
materials provided to investigational sites.   
Any remaining retainable biological samples will be stored at the central laboratory or designee 
at the latest until the marketing authorization. These samples may be used for future additional 
analysis in the context of the E4/DRSP development program.  
At Visit 1 and 7, blood hematology, biochemistry and lipids will be assessed (see Appendix 
2). At Visit 5, the following biochemistry parameters will be assessed: glycaemia, glycated 
hemoglobin, total cholesterol, HDL- and LDL-cholesterol, triglycerides, Lactate 
dehydrogenase (LDH) 1 and LDH 2, renal function (urea, creatinine, and glomerular filtration 
rate [GFR]) and ionogram (Na, K, Cl, Ca2+, P, HCO3-). Subject should be fasting for 8 hours 
before blood collection. 
All out-of-range laboratory values that are considered by the Investigator to be clinically 
significant will be recorded as AEs (see Section 9.6.3.1) 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 52 of 114 
9.6.3.4 
Physical Examination 
A physical examination will be performed at Screening Visit and Visit 7. The physical 
examination will include an evaluation of the following: body as a whole, skin, head, eyes, 
ears, nose, and throat (HEENT), neck, cardiovascular, respiratory, musculoskeletal, 
neurologic, lymphatic/thyroid, abdomen. 
When reporting the results of the physical examination, the use of the “Abnormal” category 
will be reserved for findings that are considered clinically significant, in the opinion of the 
Investigator; the “Normal” category will include “Abnormal” results that are not clinically 
significant, as well as no findings.   
All abnormal findings will be recorded as AEs (see Section 9.6.3.1). 
9.6.3.5 
Height, Weight and Body Mass Index 
Height will be recorded at Screening Visit only. Weight will be recorded at Screening Visit, 
Visit 4, Visit 5 and Visit 7. At each center the same balance will be used for all measurements. 
Subjects will wear only indoor clothing without shoes. BMI will be calculated at the Screening 
Visit, Visit 4, Visit 5 and Visit 7 using the following formula:  
𝑊𝑒𝑖𝑔ℎ𝑡
𝐻𝑒𝑖𝑔ℎ𝑡² (kg/m²). 
9.6.3.6 
Gynecological Examination, Chlamydia test, Gonorrhea test and Cervical 
Cytology 
A gynecological examination will be performed at Screening Visit and Visit 7. The 
gynecological examination will include an evaluation of the following: breast examination 
(performed by palpation) and assessment of the adnexa, cervix, uterus, vagina, and external 
genitalia.   
When reporting the results of the gynecological examination, the use of the “Abnormal” 
category will be reserved for findings that are considered clinically significant, in the opinion 
of the Investigator; the “Normal” category will include “Abnormal” results that are not 
clinically significant, as well as no findings. 
All abnormal findings will be recorded as AEs (see Section 9.6.3.1). 
A Chlamydia testing will be performed using a vaginal swab: 
 At Screening (Visit 1) for all subjects. 
 At Visits 2, 3, 4, 5 and 6 for subjects who reported a change in sexual partner since the 
last study visit. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 53 of 114 
In case of positive Chlamydia test result, the subject will be treated, at the Investigator’s 
discretion as this infection can influence the vaginal bleeding pattern. In case of positive 
Chlamydia test result at screening, the subject will start treatment before she is enrolled.  
A gonorrhea testing will be performed using a vaginal swab: 
 At Screening (Visit 1) for all subjects.  
 At Visits 2, 3, 4, 5, and 6 for subjects who reported a change in sexual partner since the 
last study visit.  
In case of positive gonorrhea test result, the subject will be treated, at the Investigator’s 
discretion as this infection can influence the vaginal bleeding pattern. In case of positive 
gonorrhea test result at screening, the subject will start treatment before she is enrolled.  
 
For cervical cytology, Pap testing will be performed at Screening in all women 20 years 0 
months of age or older if no documented Pap test has been performed in the last 18 months.  
The enrollment visit cannot be performed until this Pap test result is available and the subject 
meets entry criteria. A copy of any Pap test or follow-up testing used for determination of study 
eligibility or during study follow-up must be obtained and included in the study record.  If not 
available at the time of the visit for which the documentation is required then the Pap test 
should be performed per protocol. The results of the Pap test will be reported using the 
Bethesda Pap Smear Classification7 as detailed in Appendix 3. If the Pap test at the Screening 
Visit presents abnormal result (i.e. dysplasia, cervical intraepithelial neoplasia, squamous 
intraepithelial lesion, carcinoma in situ, invasive carcinoma), the subject cannot be enrolled in 
the study.  Enrollment of a subject with an ASCUS interpretation is permitted if the subject is 
less than 21 years of age or HPV reflex test is negative for high-risk oncogene virus. If the 
ASCUS interpretation was done on the Pap test performed in the past 18 months, enrollment 
of the subject is allowed if a repeat Pap test 6 months later was normal.   
All abnormal findings in cervical cytology after subject enrolment that are considered by the 
Investigator to be clinically significant will be recorded as AEs (see Section 9.6.3.1). 
9.6.3.7 
Vital Signs 
Vital signs will be measured at Screening Visit, Visits 2, 3, 4, 5, 6, and 7. 
Vital signs will include sitting systolic and diastolic blood pressures and heart rate. Blood 
pressure measurements will be made using a sphygmomanometer with an appropriate cuff size 
for the individual subject.  Measurements will be taken while the subject is seated after at least 
5 minutes at rest. 
All abnormal findings in vital signs that are considered by the Investigator to be clinically 
significant will be recorded as AEs (see Section 9.6.3.1). 
9.6.4 
Other Evaluations 
Other assessments include the following: 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 54 of 114 
- 
Vaginal bleeding pattern will be assessed based on the incidence of vaginal 
bleeding/spotting episodes; 
- 
Compliance will be assessed based on tablet intake;  
- 
Demographics; 
- 
Prior/Concomitant medication use; 
- 
Medical/surgical history; 
- 
Gynecological history; 
- 
Pregnancy risk and back-up contraception use; 
- 
Acceptability of trial medication; 
- 
Subjects’ well-being; 
- 
Contraceptive counseling; 
- 
Return of spontaneous menstruation and return to fertility. 
9.6.4.1 
Incidence of vaginal bleeding/spotting  
Subjects will be asked to record in the subject diary (see Section 9.6.1) the absence or the 
occurrence of vaginal bleeding or spotting on a daily basis using the following definitions: 
0 = Absence of vaginal bleeding or spotting; 
1 = Spotting: evidence of minimal vaginal blood loss that does not require new use of sanitary 
protection, including pantyliners; 
2 = Bleeding: evidence of vaginal blood loss that requires the use of sanitary protection with a 
tampon, pad or pantyliner. 
9.6.4.2 
Population Pharmacokinetic Substudy 
Population PK will be assessed using plasma E4 and DRSP concentration data from a subset 
of approximately 500 subjects to address the relationship between PK parameters and various 
individual characteristics (e.g., body weight, race, smoking, and fed/fasted condition). Blood 
samples for PK analysis will be obtained at Visits 3 and 4 between Days 10 and 14 of Cycles 
2 and 4.  
All subjects enrolled in the Population PK Substudy will be required to check-in to the site for 
Visits 3 and 4 between Days 10 and 14 of Cycles 2 and 4, respectively. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 55 of 114 
Two PK samples will be taken from the subjects in the Population PK Substudy at Visits 3 and 
4. All subjects included in the Substudy will provide a sample for PK analysis at the time they 
check into the site (PK sampling 1). An additional blood sample (PK sampling 2) will be 
collected approximately two hours after the first sample.  
 
Depending on the time scheduled for the study site visit (Visit 3 & 4), subjects will be 
instructed on when they need to take their medication – either as usually done at home or on 
site. 
- 
If the appointement is scheduled in the morning and the subject usually takes her study 
medication in the morning, she should take it at the study site. One blood sample will 
be taken before dosing and the second blood sample will be taken within 2-hour 
postdose.  
- 
If the appointement is scheduled in the morning and the subject usually takes her study 
medication in the evening, she should take it in the evening before the visit at their 
regular time. The subject should record the time of the dosing in the Diary.  
- 
A subject who usually takes her study medication during the day should take it at usual 
time and come to the site when possible to have the 2 blood samples taken. The subject 
should record the time of dosing in the Diary. 
The following timings will be recorded by the site personnel in the eCRF: 
- 
The exact times of the last study medication dosing and the PK samplings 1 and 2.  
- 
The time of the last meal intake before the last study medication dosing before study 
visit. 
Plasma concentration data will be used to build an appropriate population PK model. 
Only a selection of the sites will participate in the Population PK Substudy. 
9.6.4.3 
Compliance 
Compliance (see also Section 9.4.3) to the investigational product will be evaluated using data 
recorded in the subject diary. Subjects will be asked to record tablet intake in the subject diary 
(see Section 9.6.1) on a daily basis. 
9.6.4.4 
Demographics 
Demographic data include age, education, ethnicity and race. 
9.6.4.5 
Prior and Concomitant Medication Use 
Medications with an end date occurring before the first investigational product dose date in the 
treatment period will be identified as prior medications. Medications with a start date occurring 
on or after the first investigational product dose date in the treatment period or medications 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 56 of 114 
with a start date prior to the first investigational product dose date and an end date on or after 
the first treatment start date will be identified as concomitant medications. 
MEDICATION HISTORY – PRIOR MEDICATION USE 
Any medications taken in the last month prior to the Screening Visit will be recorded at 
Screening Visit and Visit 2 with the start and stop dates (see Section 9.4.6 for restrictions). 
All hormonal contraceptives used via the following routes and within the timeframe specified 
prior to the Screening Visit will be recorded and the start and stop dates will also be recorded 
as specified below: 
 Progestational implants; progestin, estrogen, or progestational injectable drug 
therapy within 12 months; 
 Intrauterine hormonal contraceptives within 6 months; 
 Oral, intravaginal or transdermal combined or progestin-only contraceptives within 
3 months. 
 
CONCOMITANT MEDICATION USE 
Subjects will be queried at Visits 3, 4, 5, 6, and 7 concerning the use of medications (see 
Section 9.4.6 for restrictions). Concurrent medications used by the subjects will be documented 
including the name of the drug, the dose, the frequency, and route of administration, the date 
of initiation and discontinuation, and the reason for administration. 
The reason for use or change of dose of a concomitant therapy may need to be reported as an 
AE (see Section 9.6.3.1). 
9.6.4.6 
Medical/Surgical History 
The medical and surgical history of the subject will be recorded at the Screening Visit. 
This includes a review of: 
- 
All body systems, 
- 
Cardiovascular 
risk 
factors: 
diabetes 
mellitus, 
dyslipoproteinemia, 
arterial 
hypertension, alcohol and illicit drug consumption, and tobacco use, 
- 
Previous surgical intervention(s), including indication, date and outcome.  
 
9.6.4.7 
Gynecological History 
The gynecological history of the subject will be recorded at the Screening Visit. 
This includes: 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 57 of 114 
- 
Gravidity and parity status; 
- 
Menstrual cycle length for starters; 
- 
Dysmenorrhea; 
- 
Previous contraceptive method used. This includes, but is not limited to COC, 
progestin-only oral contraceptive, barrier methods, intrauterine devices, etc; 
- 
History of pregnancy during accurate hormonal contraceptive use. 
 
9.6.4.8 
Pregnancy Risk and Back-up Contraception Use 
Subject will be asked to record in the subject diary (see Section 9.6.1) for each cycle the 
occurrence of intercourse and the use of back-up contraception (e.g. use of condoms) if any.  
9.6.4.9 
Contraceptive Counseling 
At Visit 6, the subject will be counseled about her future contraception. The choice of the 
contraceptive method is left to the Investigator’s discretion.  
A subject who desires early termination or is withdrawn from the study (see Section 13.4) after 
the enrollment visit (Visit 2) will be counseled about future contraception. 
 Any subject who contacts the study site with a desire to discontinue study participation 
should be instructed at each visit to contact the study staff before discontinuing the 
study drug to be counseled about alternative contraception to use prior to the Early 
Termination Visit. Study sites may provide any prescription or non-prescription 
contraceptive to the subject as is medically appropriate per local standard of care other 
than an IUD or implant. If necessary, an unscheduled visit can occur to provide 
contraception (see section 9.5.5). 
 A subject who presents to the study site for a scheduled visit and desires to discontinue 
study participation or is withdrawn from the study at that visit should be counseled 
about alternative contraception to use prior to the Early Termination Visit. Study sites 
may provide any prescription or non-prescription contraceptive to the subject as is 
medically appropriate per local standard of care other than an IUD or implant. 
 A subject who presents to the study site for a scheduled visit who has not taken the 
study product for 16 days or more should have the scheduled visit procedures and the 
Early Termination Visit procedures completed at that time. The subject should be 
counseled about alternative contraception. Study sites may provide any prescription or 
non-prescription contraceptive to the subject as is medically appropriate per local 
standard of care. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 58 of 114 
On the day the subject is expected to start this contraception (± 1 day), the 
Investigator/Designee will contact the subject by phone to ensure her compliance with the 
counseled contraceptive method.  
9.6.4.10 
Acceptability of Trial Medication 
The acceptability of the trial medication will be assessed by analysis of discontinuation rates 
and reasons for discontinuations. Subject’s premature discontinuation must be documented on 
the Treatment Discontinuation Form, including the most important reason for discontinuation. 
The most important reason for discontinuation will be categorized as AE, lost to follow-up, 
subject request, protocol deviation, pregnancy, pregnancy wish or other. Subjects that complete 
the study must be documented on the End of Study Form. 
9.6.4.11 
Subjects’ well-being 
Subjects’ well-being will be evaluated using two well-established questionnaires: the Quality 
of Life Enjoyment and Satisfaction Questionnaire – Short Form and the Menstrual Distress 
Questionnaire.  
The baseline questionnaires will be given to the subject at Visit 2. The subject will be instructed 
to fill them in at home on or before the first day of study medication intake (Day 1). At the 
next visit, the study site personnel will ensure for the questionnaire completion. 
The end-of-treatment questionnaires will be given to the subject at Visit 6. The subject will be 
instructed to fill them in at home between Day 7 and Day 14 of the 13th treatment cycle. At the 
next visit, the study site personnel will ensure for the questionnaire completion. 
In case of premature study discontinuation, the subjects will be asked to fill in the 
questionnaires during the Early Termination Visit. 
  
9.6.4.12 
Return of spontaneous menstruation and return to fertility 
Each woman who discontinues the study early due to a pregnancy wish will be followed after 
study treatment discontinuation to evaluate return of spontaneous menstruation and return of 
fertility.  
They will be contacted every 6-8 weeks for a maximum of one year after study discontinuation. 
The date of the first spontaneous menstruation after study discontinuation will be recorded in 
the eCRF and follow-up will be continued. Once a pregnancy is reported or once a new 
contraceptive method has been started, the expected date of pregnancy term or of contraceptive 
treatment initiation will be recorded in the eCRF and no further follow-up contact will be done. 
In case of pregnancy, the estimated date of conception will be derived from the expected date 
of pregnancy term.

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 59 of 114 
10 ETHICS 
10.1 Ethics Committee 
The protocol and supporting documents for this study will be reviewed and approved by an 
appropriately constituted IRB prior to study initiation. 
All reviews and approvals will be in accordance with Good Clinical Practice (GCP) as 
contained in the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) Guidelines (E6) and United States (US) 
CFR governing Institutional Review Boards (IRBs) (Title 21, Part 56). 
A letter from the IRB documenting approval of the Investigator (who must be identified by 
name), the protocol (must be identified by title) and the subject consent form must be received 
by Estetra SPRL (referred hereafter as Sponsor) or its Designee prior to study initiation.  A 
progress report will be submitted by the Investigator to the IRB at intervals specified by the 
IRB, but not less than annually.  A copy of this progress report will be sent to Sponsor.  After 
completion of the study, the Investigator will submit a signed clinical safety summary of the 
study to the IRB. 
10.2 Ethical Conduct of Study 
The study will be conducted in accordance with GCP as contained in ICH Guidelines and US 
CFR governing the protection of human subjects (Title 21, Part 50) and the obligations of 
clinical Investigators (Title 21, Parts 312.60 through 312.69).  The study will also be conducted 
in accordance with the World Medical Association Declaration of Helsinki and all 
amendments. 
Sponsor or Designee is responsible for the ongoing safety evaluation of the investigational 
product and will expedite the notification of all participating Investigators and regulatory 
authorities of findings that are both serious and unexpected and/or that could adversely affect 
the safety of subjects, the conduct of the study or alter the IRB’s approval to continue the study. 
10.3 Subject Information and Consent 
The Investigator will ensure that written IC is obtained from each subject in accordance with 
applicable regulations. 
Subjects will be interviewed at the Screening Visit by qualified staff at the site and will be 
provided with a full description of the nature and purpose of the study. The subject will be 
given adequate time to consider the requirements and risks associated with participation in the 
study.  Each subject will provide written and signed IC prior to participating in any study 
procedures.  The original signed consent forms will be retained on file at the clinical site and 
a copy will be given to the subject. Source documentation will also document that IC was 
obtained prior to the subject’s participation in the study.  

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 60 of 114 
10.4 Subject Confidentiality 
The Sponsor ensures that the following have permission to review all study-related documents: 
monitor, auditor, IRB and regulatory authorities. The subject’s identity and study-related 
records will remain confidential throughout the duration of the study data collection and 
reporting process. 
A unique subject identification code will be assigned to each potential study subject.  The 
identification code protects the subject’s identity and is used in lieu of the subject’s name when 
reporting subject data.  The data will always maintain the confidentiality of the subject. 
The Investigator or Designee will review the subject data, which will be referenced using the 
subject identifier. At the conclusion of the study, the data obtained may be presented to regional 
regulatory authorities but the subject’s identity will not be revealed.  In addition, if any clinical 
data obtained from the study are published in scientific journals or presented at scientific 
meetings, the subject’s identity will not be revealed. 
 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 61 of 114 
11 QUALITY CONTROL AND ASSURANCE 
The Sponsor and Designee will implement and maintain quality control procedures to ensure 
that this study is conducted and data are generated, documented, and reported in compliance 
with the protocol, GCP and applicable regulatory requirements. 
The Sponsor or Designee will routinely conduct monitoring and/or auditing visits to the study 
centers to verify the adherence to the study protocol, the protection of the rights and well-being 
of the subjects; and the accuracy and completeness of reported study data recorded on the 
source documentation. 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 62 of 114 
12 PLANNED STATISTICAL METHODS 
Detailed plans for the statistical methods will be provided in a Statistical Analysis Plan which 
will be finalized prior to database lock. 
12.1 Determination of Sample Size 
Sample size is based on needing a sufficient number of cycles such that the difference between 
the Pearl Index and the upper limit of the two-sided 95% confidence interval (CI) for the Pearl 
Index does not exceed 1.  Assuming that the true Pearl Index is 1.0 and that a Poisson model 
is used to derive the CIs, then at least 12,337 at risk cycles are required for a power of 90% in 
the 16 to 35 year old population.8. If a not at risk cycle rate of 20% and a dropout rate of 
approximately 45% (assuming that we have an average of 4 cycles for subjects that 
discontinue) are assumed, approximately 1800 16 to 35 year old subjects need to be enrolled 
and initiate the investigational product.  Additionally, it is planned for a maximum of 200 
subjects > 35 years to be enrolled and initiate the investigational product. Therefore, in total, 
approximately 2000 subjects will be enrolled in the study and initiate the investigational 
product. Additionally, a subset of approximately 500 subjects will be enrolled in the PK 
Substudy. 
12.2 Analysis Populations and Datasets 
Statistical analysis and data tabulation will be performed using the following analysis 
populations unless specified otherwise: 
 Screened population includes all subjects who signed an IC form. 
 Enrolled population includes all enrolled subjects. 
 Safety population includes all enrolled subjects who receive at least one dose of test 
article. 
 Intention-to-Treat (ITT) population includes all enrolled subjects who receive at least 
one dose of test article.  The ITT population is the same as the Safety population for 
this study. 
 Per-protocol (PP) population includes all subjects in the ITT population who complete 
the study and do not have any important protocol deviations that impact the statistical 
analysis. The PP population may differ for the different endpoints. 
 PK population includes all subjects enrolled in the PK Substudy who provide 
concentration data for at least one sample. 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 63 of 114 
12.3 General Statistical Procedures  
All the analyses will be conducted with SAS using procedures appropriate for the particular 
analysis. 
The descriptive statistics for all the continuous variables presented will be mean, median, 25th 
percentile, 75th percentile, standard deviation (SD), standard error of mean (SEM), minimum, 
maximum, and number of subjects.   
Categorical variables will be summarized using counts and percentages. 
Baseline will be defined as the most recent assessment prior to first dose of study medication. 
12.4 Efficacy Analyses 
The efficacy analysis will be based on the Pearl Index. The Pearl Index, defined as the 
number of pregnancies per 100 women-years of treatment, will be calculated as 
𝑃𝑒𝑎𝑟𝑙 𝐼𝑛𝑑𝑒𝑥=
1300 ×  number of on −treatment pregnancies
number of women −28 day equivalent cycles of treatment 
Only at risk cycles, i.e. cycles in which no other methods of birth control (including condoms) 
are used and during which the subjects confirmed that sexual intercourse has occurred, will be 
included in the denominator of the Pearl Index calculation. The subject diary data will be used 
to determine whether additional birth control methods were used and whether the subject has 
had intercourse. 
Note that if conception occurs in a cycle, then that cycle will be included in the denominator 
even if other methods of birth control were used during that cycle or the subject did not confirm 
that they had had sexual intercourse. Cycles after the cycle of conception will be excluded from 
the denominator. All on-treatment pregnancies will be included in the numerator for the Pearl 
Index.   
On-treatment pregnancy is defined as pregnancy with an estimated date of conception within 
the on-treatment period, i.e. Day 1 to 7 days after the intake of investigational product (whether 
active or inactive tablet). In cases where the date of conception cannot be established 
unequivocally (e.g. subjects is lost to follow-up), this pregnancy will be considered an on-
treatment pregnancy. For calculation purposes a cycle will be defined as 28 days. 
The method failure Pearl Index is calculated using the same method as the Pearl Index, but 
includes only those pregnancies that were classified as method failure and not pregnancies due 
to user failure, i.e. incorrect intake of the contraceptive product. Compliance data will be used 
to determine if the pregnancy was due to user failure. 
Each on-treatment pregnancy will be reviewed and classified as either a method failure or a 
user failure pregnancy prior to database lock. Pregnancies will only be designated as user 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 64 of 114 
failures if there is documentation that the subject did not use the test article correctly during 
the treatment cycle the conception occurred, including the instructions to be followed in case 
of missed pill(s). 
12.4.1 
Efficacy Endpoints 
The efficacy endpoints are: 
 Pearl Index for subjects aged of 16 to 35 years, inclusive, at screening; 
 Pearl Index for all ages; 
 Method failure Pearl Index for subjects aged 16 to 35 years old, inclusive, at screening; 
 Method failure Pearl Index for all ages. 
 
The primary efficacy endpoint will be the Pearl Index in the ITT population aged 16 to 35 
years, inclusive, at Screening with at risk cycles (cycles in which no other methods of birth 
control (including condoms) are used and during which the subjects confirmed that sexual 
intercourse has occurred). Subjects in this age group will not be censored on their 36th birthday 
for the pregnancy assessment. 
 
12.4.2 
Statistical Analysis 
12.4.2.1 
Confidence Intervals for the Pearl Indices 
The 95% CI for the Pearl Indices will be presented for the 16 to 35 year age group and overall 
and for method failure for the ITT population including only at risk cycles in the denominator. 
For historical comparison the Pearl Index will also be calculated using the same method as 
described above including all at risk cycles and cycles where the subject did not have 
intercourse and did not use back-up contraception in the denominator. 
The 95% CI for Pearl Indices will be calculated based on using a Poisson distribution.   
12.4.2.2 
Life-Table Rates  
In addition, the cumulative pregnancy rate, as determined by life-table methods, together with 
the corresponding 95% CIs will be presented for all pregnancies and for all method failure 
pregnancies in the ITT population. This will be repeated for all ages and for subject’s age 16 to 
35 years inclusive at Screening. 
Life-table analyses will provide one-year life-table pregnancy rates for each efficacy endpoint 
(i.e. for all pregnancies as used in the Pearl Index and for all method failure pregnancies as used in 
the method failure Pearl Index).  The life-table analysis will evaluate the cumulative probability 
of pregnancy by cycle using PROC LIFETEST in SAS where the time variable is the cycle 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 65 of 114 
where the estimated conception occurred for subjects who had an on-treatment event of 
pregnancy. Subjects who did not have an on-treatment event of pregnancy will be censored on 
the cycle at which they discontinued from the study. Cumulative probabilities of pregnancy 
and 95% CIs will be calculated based on Kaplan-Meier estimates through Cycle 13. 
Additionally, the estimated survivor function against time (cycle) will be provided. 
12.4.3 
Statistical Subgroup Analyses  
If the sample size is adequate, subgroup analyses will be performed for the following 
categories: 
 BMI categories (< 30, ≥ 30); 
 Race category (White, Black, Asian, Other); 
 Starters/Switchers; 
 Smokers/Non-smokers; 
 Age (16-25; 25-35 and > 35 years old). 
12.5 Safety Analyses 
Safety variables will be summarized for the Safety population using descriptive statistics and 
frequency distributions as defined in the following sections.  
12.5.1 
Adverse Events 
TEAEs will be classified into a standardized terminology using the Medical Dictionary for 
Regulatory Activities (MedDRA) system organ classifications and preferred terms.  The latest 
available version of MedDRA will be used as coding dictionary.  Prior to database lock, the 
coding will be updated using the current version of MedDRA.  The incidence of TEAEs will 
be summarized for the Safety population.  Although a preferred term or system organ class 
may be reported more than once for a subject, each subject will only be counted once in the 
incidence count for that preferred term or system organ class.  Summaries of the following 
types will be provided: 
• Overall summary of TEAEs. 
• Summary of TEAEs by MedDRA system organ class, MedDRA preferred term, 
investigational product relationship, and intensity. 
• Summary of TEAEs by MedDRA preferred term and investigational product relationship 
in descending order of frequency. 
• Summary of treatment-emergent SAEs by MedDRA system organ class, MedDRA 
preferred term, and investigational product relationship. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 66 of 114 
• Summary of TEAEs by MedDRA system organ class, MedDRA preferred term, and 
investigational product relationship for the primary events leading to premature 
discontinuation from the study. 
 
These summaries will present the number and percentage of subjects reporting an AE for each 
classification level as well as the number of events reported.  The denominator for calculating 
the percentages for summaries will be based on the number of subjects in the overall Safety 
population. 
All AEs, SAEs and deaths, SAEs considered to be related to treatment, and AEs leading to 
premature discontinuation from the study will also be provided in data listings including non-
treatment emergent events. 
12.5.2 
Extent of Exposure 
The duration of exposure in days will be summarized using descriptive statistics for the 
Safety/ITT population.  Duration of exposure will be calculated as the difference between last 
tablet intake date and the first tablet intake date plus 1.  
Additionally, these summaries will present the number and percentage of subjects exposed for 
at least 26 weeks and at least 52 weeks. The denominators for calculating the percentages will 
be based on the number of subjects in the Safety population. 
12.5.3 
Clinical Laboratory Evaluations 
For continuous clinical laboratory analytes, the absolute value and change from baseline will 
be summarized by analyte and visit using descriptive statistics for the Safety population.  
Categorical laboratory analytes, classified as normal or abnormal, will be summarized by 
analyte and visit using the number and percentage of subjects in each category for the Safety 
population.  The denominators for calculating the percentages will be based on the number of 
subjects with non-missing assessments at a particular visit for the Safety population. 
Shifts to values outside of the normal range will be presented by analyte and visit and will be 
summarized by the number and percentage of subjects with evaluable shifts. An evaluable shift 
is one where both the Screening Visit value and the on-treatment or early termination value 
are recorded for subjects in the Safety population. The denominators for calculating the 
percentages will be the number of subjects with an evaluable shift. 
All clinical laboratory values, abnormal clinical laboratory values, and clinical significant 
laboratory values will also be provided in data listings. 
12.5.4 
Physical examination 
Physical examination assessments will be summarized for the Safety population by visit.  For 
each body system and assessment category, the number and percentage of subjects will be 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 67 of 114 
presented.  The denominators for calculating the percentages will be based on the number of 
subjects evaluated for a particular body system. 
12.5.5 
Gynecological examination 
Gynecologic examination assessments will be summarized for the Safety population by visit.  
For each assessment category, the number and percentage of subjects will be presented.   
12.5.6 
Vital Signs 
Vital sign measurements for the Safety population will be summarized using descriptive 
statistics by visit.  The change from baseline will also be summarized in the same manner. 
12.5.7 
Height, Weight and BMI 
Weight measurements and BMI calculation for the Safety population will be summarized using 
descriptive statistics by visit.  The change from baseline will also be summarized in the same 
manner. 
Height at baseline (Visit 1) will be summarized using descriptive statistics. 
12.6 Other Assessments or Analyses 
12.6.1 
Bleeding and spotting 
Bleeding/spotting data will be summarized according to the methods suggested by Mishell et 
al. 9.   

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 68 of 114 
Table 1: Bleeding and spotting definitions 
Term 
Definition 
Bleeding  
Evidence of vaginal blood loss that requires the use of sanitary 
protection with a tampon, pad or pantyliner. 
Spotting 
Evidence of minimal vaginal blood loss that does not require new use of 
sanitary protection, including pantyliners. 
Episode of 
Bleeding/Spotting 
Bleeding/spotting days bounded on either end by 2 days of no bleeding 
or spotting. 
Scheduled 
Bleeding/Spotting 
Any bleeding/spotting that occurs during the hormone-free interval (i.e. 
Days 25 – 28) and continues through Days 1-3 of the subsequent active 
cycle, 
and 
Any bleeding/spotting that occurs while taking active hormones during 
Days 1-7 of the first cycle. 
Unscheduled 
Bleeding 
Any bleeding that occurs while taking active hormones that does not 
meet the criteria for scheduled bleeding. 
Unscheduled 
Spotting 
Any spotting that occurs while taking active hormones that does not 
meet the criteria for scheduled spotting. 
 
Bleeding patterns will be analyzed in the ITT and PP populations using data from the subject 
diary. Criteria for exclusion of cycles from the PP analysis of bleeding patterns will be defined 
in the statistical analysis plan (SAP) based on specific protocol deviations thought to have a 
potential to impact the subjects bleeding patterns that occurred during that cycle. Vaginal 
bleeding will be classified as spotting or bleeding and scheduled and unscheduled based on the 
definitions in Table 1.  
There will be two types of reference periods (RP) evaluated for this study: 
 Reference period based on 28-days (or cycle) – 13 cycles 
 Reference period based on 91 days  
The analysis will include all subjects in the respective analysis population with at least 1 
evaluable reference period.  One or two consecutive days with missing bleeding information 
will be interpolated with the bleeding information from the previous day.  For three or more 
consecutive days with missing bleeding information, missing data will be interpolated using 
the worst bleeding observation of the bordering days. 
Summaries of bleeding/spotting data include but are not limited to the following: 
 Number and percentage of subjects with unscheduled bleeding and/or spotting 
episodes for each reference period. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 69 of 114 
 Percentage of subjects with bleeding and/or spotting including both scheduled and 
unscheduled for each day presented in a graphical display. 
 Number and percentage of subjects with absence of any bleeding or spotting for each 
reference period. 
 Descriptive statistics (e.g., mean, SD, median, minimum, and maximum) for the 
number of days of bleeding and/or spotting, bleeding only, and spotting only within a 
reference period for: 
o Total Days (Unscheduled + Scheduled) 
o Unscheduled Days 
o Scheduled Days 
Additionally, bleeding data may be summarized for some subgroups specified in Section 
12.4.3.  
12.6.2 
Disposition 
The disposition of subjects will be summarized including the number of subjects screened, 
enrolled, treated, discontinued (including reason for discontinuation) and completed. In 
addition, the number of subjects included in each of the analysis populations will be 
summarized. The cumulative discontinuation rate, as determined by life-table methods, 
together with the corresponding 95% CIs will be presented.   
12.6.3 
Demographic and Other Pre-treatment Characteristics 
Subject demographic as well as medical history will be summarized for each analysis 
population using descriptive statistics for continuous variables and frequency distributions 
(number and percentage of subjects) for categorical variables.  Summaries will be provided 
overall and by race and BMI categories in the Safety/ITT and PP populations. 
 
12.6.4 
Prior and Concomitant Medications 
Medication usage will be coded using the World Health Organization (WHO) Drug Dictionary. 
Medications will be presented by WHO Drug Anatomical/Therapeutic/Chemical category and 
WHO Drug preferred name. Summaries will be presented for prior (prior to treatment period) 
medication use and concomitant (during treatment period) medication use. 
Medications with an end date occurring before the first investigational product dose date in the 
treatment period will be identified as prior medications.  Medications with a start date 
occurring on or after the first investigational product dose date in the treatment period or 
medications with a start date prior to the first investigational product dose date and an end date 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 70 of 114 
on or after the first investigational product dose date will be identified as concomitant 
medications. All summaries will present the number and percentage of subjects for each 
medication. The denominators for calculating the percentages will be based on the number of 
subjects in the Safety population. 
12.6.5 
Treatment Compliance 
Treatment compliance by cycle will be presented using the subject diaries based on number of 
tablets taken divided by the number of tablets that should have been taken. The number and 
percentage of subjects missing no tablets, 1 tablet, 2 tablets and more than 2 tablets will be 
summarized for each cycle. Summaries will be presented using descriptive statistics in the 
Safety population. 
12.6.6 
 Protocol Deviations 
The number and percentage of subjects who had an important protocol deviation will be 
summarized for the enrolled population. 
12.6.7 
Quality of Life 
The total score of the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form 
(Q-LES-Q-SF) (Appendix 4) will be derived by summing the first 14 items to obtain the raw 
total score, which is then transformed into a percentage maximum using the following formula: 
(raw score – 14)/56. The absolute values and change from baseline of the percentage 
maximum, how satisfied the subject has been with the medication and how would the subject 
rate the overall life satisfaction and contentment during the past week will be summarized 
descriptively by visit. 
The Menstrual Distress Questionnaire will be scored according to the manual (Appendix 5) 10. 
The absolute values and change from baseline for the scores for pain, water retention, 
autonomic reactions, negative affect, impaired concentration, behavior change, arousal and 
control will be summarized descriptively by visit. Summaries will be provided overall and by 
switchers and starters separately. 
12.6.8 
Follow-Up Evaluations 
The number and percentage of subjects who had pregnancy confirmation, returned to menses 
and received a new contraceptive method after the treatment termination will be summarized. 
The denominator used for the percentages will be the number of subjects in the Safety 
population who discontinued study medication due to a pregnancy wish. 
The time from last dose of study medication to return of menses will be summarized using 
descriptive statistics in the Safety population.  

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 71 of 114 
The following will be summarized using descriptive statistics for subjects in the Safety 
population who discontinued study medication due to a pregnancy wish who selected the 
corresponding fertility information: 
 Time from last dose of study medication to estimated date of conception; 
 Time from last dose of study medication to new contraceptive method. 
 
12.6.9 
Population Pharmacokinetic Substudy 
Plasma concentration data for E4 and DRSP will be summarized using descriptive statistics by 
cycle and sampling time range (ranges will be defined in the Statistical Analysis Plan) for the 
PK population. Descriptive summaries will be provided overall and by race, BMI categories 
(< 30, ≥ 30), smoking status (smokers, non-smokers), and fed/fasted condition. Additionally, 
concentration data will be displayed graphically with regression lines overall, and by race, BMI 
categories, and smoking status for each cycle. 
Individual plasma concentration-time data will be pooled for the PK analyses. Initially, the 
data will be subjected to exploratory compartmental analysis to determine the primary 
parameters such as: 
 Apparent clearance (CL/F). 
 Central volume of distribution (V/F). 
 Lag time of Absorption (tlag), if necessary. 
 Relative bioavailability for fed vs fasted state. 
The initial estimates obtained from the exploratory analyses will be employed using Bayesian 
analysis to build an appropriate population PK model. The analyzed parameters will include, 
but not be limited to: 
 Maximum concentration (Cmax). 
 Time to maximum concentration (Tmax). 
 Extent of exposure for dosing interval (AUCtau). 
 Terminal half-life (t1/2). 
The estimated population mean values will be utilized in conjunction with the individual 
subject concentrations to determine inter-individual variability. If inter-individual variability 
is unable to be assessed on any individual parameter, the population mean values alone may 
be used. The impact of individual characteristics on the parameters will be explored and 
included in the population model if significant. Individual estimates of the above parameters 
and additional PK variables will be generated based on the population model. The basic model 
will be evaluated for random scatteredness by residual variability analysis. The model will 
further be validated using various diagnostic techniques, as necessary. Covariate analyses will 
be performed separately for the PK of E4 and DRSP. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 72 of 114 
13 STUDY MANAGEMENT 
13.1 Monitoring 
The Investigator will be responsible for preparing and maintaining adequate and accurate 
source documents (medical records, raw data collection forms, etc.) designed to record all 
observations and other pertinent data for each subject treated with the study drug.  The 
Investigator will allow representatives of the Sponsor, contract Designees, authorized 
regulatory authority inspectors, and the ECs to have direct access to all documents pertaining 
to the study.  The Investigator is to immediately notify the Sponsor (or its representative) of 
any regulatory authority inspections.  The Investigator will be informed about the outcome of 
any Sponsor audit. 
This study will be monitored regularly, by or under supervision of a monitor from the Sponsor’ 
representative.  The frequency of monitoring visits will be agreed upon by the Sponsor’s 
representative and the study staff.  
Monitoring visits will take place on a regular basis according to the enrollment rate and number 
of subjects enrolled at each investigational site.  During these visits, the monitor will check the 
completion of the eCRF entries, compliance with the study protocol and with GCP - ICH, and 
their agreement with the source data.  The monitor will also verify the correct use of the study 
drug.  At a final visit, the monitor will check all remaining material including the remaining 
quantities of the study drug and will organize their return to the Sponsor or Designee.  At each 
visit, the Investigator and staff will be expected to cooperate with the Sponsor’s 
representative(s) for the purposes of review and verification of protocol compliance, AE 
reporting, eCRFs, source documents, clinical supplies and inventory records, and any 
additional records as may have been previously arranged between the Investigator and the 
Sponsor’s representative(s). 
The Investigator and/or other designated study personnel are expected to contact the Sponsor’s 
representative with any study concerns and/or questions. Contact details are provided in the 
Site Operations Manual for the site. 
13.2 Protocol amendments 
The Sponsor may propose to amend this protocol at any time. 
No change to the protocol will be implemented until the Sponsor, the competent authorities 
and the IRB have reviewed and approved the amendment. 
In the event of an emergency, the Investigator shall implement any medical procedures deemed 
appropriate for subject safety.  All such procedures must have written documentation and be 
promptly reported to the Sponsor. 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 73 of 114 
13.3 Protocol deviations 
A protocol deviation is any change, divergence or departure from the IRB approved protocol 
(intentional or unintentional). All deviations are to be documented at the site and reported to 
the IRB according to the IRB’s guidelines. 
In the event of an emergency, the Investigator shall implement any medical procedures deemed 
appropriate for subject safety. All such procedures must have written documentation and be 
promptly reported to the Sponsor.   
13.4 Withdrawal of Subjects 
Withdrawn subjects are those who do not complete all evaluations and procedures outlined in 
the protocol. Subjects who discontinue taking study drug for any reason must also be 
withdrawn from the study. Subjects may be withdrawn from the study because of one of the 
following: 
 Adverse Event: An AE that, in the opinion of the Investigator or Sponsor, suggests 
that continued participation in the study is not in the subject’s best interest for safety 
reasons.  The occurrence of a VTE or an arterial thromboembolic event will 
automatically lead to the immediate cessation of the study drug and is an absolute 
reason for discontinuing the subject participation in the trial. Only 1 AE can be 
noted to be the reason for withdrawal.  All AEs that are present when the subject 
withdraws from the study will be followed as described in Section 9.6.3.1. 
 Lost to Follow-up: Confirmed at minimum by two phone calls and a traceable letter 
without answer. 
 Subject Request: Subject requests for any reason to be withdrawn or withdraws her 
consent. 
 Protocol Deviation: A subject may be withdrawn from the study at the discretion 
of the Investigator or Sponsor due to poor compliance with protocol requirements 
that may compromise the study results or subject safety. 
 Pregnancy: If a subject becomes pregnant during the study, the subject will be 
withdrawn from the study and followed through conclusion of the pregnancy. 
 Pregnancy wish. 
 Other: Other reasons include but are not limited to: Investigator decision that it is 
in the subject’s best interest to be withdrawn, administrative reasons, relocation of 
subject, etc.   
If a subject is withdrawn from the study after enrolment visit (Visit 2), all Visit 7 assessments 
should be completed (see Section 9.5.3.5) and the subject should be counseled about alternative 
contraception to use (see Section 9.6.4.9).  Subjects withdrawn from the study will not be 
replaced. 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 74 of 114 
13.5 Termination of the Study 
If the study is terminated prematurely or suspended, the appropriate IRB and regulatory 
authority(ies) will be promptly informed of the termination or suspension and will be provided 
the reason(s) for the termination or suspension.  All obligations and responsibilities of the 
Sponsor and the Investigator under GCP, the US CFR and the Declaration of Helsinki will 
remain in force if the study is terminated prematurely. 
 
 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 75 of 114 
14 DOCUMENTATION REQUIREMENTS AND RECORDKEEPING 
14.1 Source Documentation, Data access and Monitoring 
The eCRFs represent a record of the subject’s experience in the study, therefore, the eCRF data 
must be supported by original (or source) medical records, as appropriate. EMR (Electronic 
Medical Records)  recorded directly into the eCRF is also considered source data when there 
are no other written or electronic records preceding the eCRF entry. 
Prior to enrolling a subject in the study, the Investigator must document his/her review of 
subject eligibility criteria in the source records for the subject, including the Investigator’s 
signature and date on any medical and laboratory reports indicating a review of the source data 
occurred.  The Investigator will continue to follow this practice for any subsequent medical 
and laboratory reports generated as a result of the clinical study. 
The Investigator agrees that the Sponsor or its designated agents, the IRB, the EMA, FDA or 
foreign regulatory agencies will have reasonable access to study source documentation for 
purposes of audit or inspection and monitoring visit review both during and after completion 
of the study. Monitoring visits provide the Sponsor and Designee with the opportunity to 
evaluate the progress of the study; to verify the accuracy and completeness of eCRFs; to ensure 
that all protocol requirements, applicable regulations and Investigator's obligations are being 
fulfilled; and to resolve any inconsistencies in the study records.   
14.2 Data Capture in electronic CRFs and Discrepancy Management 
Site personnel will be responsible for the completion and correction of eCRFs according to the 
protocol and other instructions provided by the Sponsor or their Designee. The Investigator is 
responsible for ensuring the completeness and accuracy of the data as evidenced by the 
Investigator’s signature and date once the subject has completed the study and all required 
study data has been entered into the eCRF. Information recorded by the subject into a Diary 
Card will be entered into the eCRFs by the site personnel.   
Since site personnel will enter data directly into a validated eCRF, programmatic data 
validation procedures will be employed to identify data discrepancies to site personnel at the 
time of entry and/or upon saving the data.  Designated site personnel will resolve any 
discrepancies via the eCRF.  Any additional findings upon clinical review by the Sponsor or 
their Designee will be entered into the system for review and resolution by site personnel.  A 
full audit trail of data changes following entry will be captured during the study in the 
electronic data management system.  The Investigator will be provided with a copy of all eCRF 
data for retention. 
14.3 RECORD KEEPING 
In compliance with ICH guidelines, the Investigator shall maintain adequate records for the 
study including copies of eCRFs for individual subjects, medical records, laboratory reports, 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 76 of 114 
consent forms, test article disposition records, safety reports, information regarding 
participants who discontinued and other pertinent data. The Investigator shall maintain these 
records for a period of at least 2 years after the last approval of a marketing application in an 
ICH region and until there are no pending or contemplated marketing applications in an ICH 
region, or at least 2 years have elapsed since the formal discontinuation of clinical development 
of the test article. These records should be retained for a longer period if required by the 
applicable regulatory requirements or by an agreement with the Sponsor. The Sponsor will 
inform the Investigator/institution as to when these records no longer need to be retained. 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 77 of 114 
15 OTHER INFORMATION 
15.1 Financing and Insurance 
Financing and insurance is addressed in a separate agreement. 
15.2 Publication and Disclosure Policy 
The data that will be obtained in this study will be the property of the Sponsor, who will make 
reasonable efforts to assure that the results are published in a peer-reviewed journal. As some 
of the information concerning the investigational product and development activities at the 
Sponsor may be of strictly confidential nature, any manuscript or other presentation of data 
must first be reviewed by the Sponsor before its submission. 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 78 of 114 
16 REFERENCE LIST 
 
1 
Duijkers, I. J. et al. Inhibition of ovulation by administration of estetrol in 
combination with drospirenone or levonorgestrel: Results of a phase II dose-finding 
pilot study. The European journal of contraception & reproductive health care : the 
official journal of the European Society of Contraception 20, 476-489, 
doi:10.3109/13625187.2015.1074675 (2015). 
2 
Mawet, M. et al. Unique effects on hepatic function, lipid metabolism, bone and 
growth endocrine parameters of estetrol in combined oral contraceptives. The 
European journal of contraception & reproductive health care : the official journal of 
the European Society of Contraception, 1-13, doi:10.3109/13625187.2015.1068934 
(2015). 
3 
Lockwood, C. & Watkins, T. A. FDA. Advisory Committee for Reproductive Health 
Drugs meeting. Final Summary Minutes. (2007). 
4 
Kapp, N., Curtis, K. M. & Borgatta, L. Study design to evaluate the safety and 
effectiveness of hormonal contraception for women. Clin.Obstet.Gynecol. 50, 850-
867, doi:10.1097/GRF.0b013e318159bf8a [doi];00003081-200712000-00003 [pii] 
(2007). 
5 
EMEA. The EMEA CHMP guideline on clinical investigation of steroid 
contraceptives in women. 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/
09/WC500003349.pdf (2005). 
6 
Division of Reproductive Health, N. C. f. C. D. P., Health Promotion, C. f. D. C. & 
Prevention. U.S. Selected Practice Recommendations for Contraceptive Use, 2013: 
adapted from the World Health Organization selected practice recommendations for 
contraceptive use, 2nd edition. MMWR Recomm Rep 62, 1-60 (2013). 
7 
Nayar, R. & Wilbur, D. C. The Pap Test and Bethesda 2014. "The reports of my 
demise have been greatly exaggerated." (after a quotation from Mark Twain). Acta 
Cytol 59, 121-132, doi:10.1159/000381842 (2015). 
8 
Gerlinger, C., Endrikat, J., van der Meulen, E. A., Dieben, T. O. & Dusterberg, B. 
Recommendation for confidence interval and sample size calculation for the Pearl 
Index. Eur.J.Contracept.Reprod.Health Care 8, 87-92 (2003). 
9 
Mishell, D. R., Jr. et al. Recommendations for standardization of data collection and 
analysis of bleeding in combined hormone contraceptive trials. Contraception 75, 11-
15, doi:S0010-7824(06)00325-8 [pii];10.1016/j.contraception.2006.08.012 [doi] 
(2007). 
10 
Moos, R. H. The development of a menstrual distress questionnaire. Psychosom Med 
30, 853-867 (1968). 
 
 

 
 
  
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
 
 
Confidential 
Page 79 of 114 
17 APPENDICES 
Appendix 1 
Study Schedule of Events  
Appendix 2 
Clinical Laboratory Evaluations 
Appendix 3 
Bethesda Pap Smear Classification 
Appendix 4 
Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-
LES-Q-SF) 
Appendix 5 
Menstrual Distress Questionnaire (Form C-Cycle) 
Appendix 6 
Sponsor Signatures 
Appendix 7 
Contract Research Organization Signatures 
Appendix 8 
Investigator Signature 
Appendix 9 
Protocol Amendment – Summary of changes 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 80 of 114 
Appendix 1. 
Study Schedule of Events 
Table 2: Schedule of Events 
Visit 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
Visit 5 
Visit 6 
Visit 7 
 
Early 
Termination 
Visit12 
Treatment Cycle 
Screening 
Visit 
Subject 
Enrollment1 
During Cycle 
2 
During Cycle 
4 
During Cycle 
7 
During Cycle 
10 
During Cycle 
14  
 
Treatment Cycle 
Day 
 
 
Cycle Day 
1 – 1411 
Cycle Day 
1 - 1411 
Cycle Day 
1 - 14 
Cycle Day 
1 – 14 
Cycle Day 
16-23 
 
Informed Consent 
X 
 
 
 
 
 
 
 
Inclusion/Exclusion 
Criteria 
X 
X 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
Medical and 
surgical History 
X 
 
 
 
 
 
 
 
Gynecological 
History 
X 
 
 
 
 
 
 
 
Physical 
Examination 
X 
 
 
 
 
 
X 
X 
Weight, Height and 
BMI2 
X 
 
 
X 
X 
 
X 
X 
Gynecological 
Examination 
(including breast) 
X 
 
 
 
 
 
X 
X 
Cervical Cytology 
(Pap)3 
X 
 
 
 
 
 
 
 
Chlamydia Testing 
X4 
X5 
X5 
X5 
X5 
X5 
 
 
Gonorrhea Testing 
X4 
X5 
X5 
X5 
X5 
X5 
 
 
Blood sample for 
Population PK 
Substudy6 
 
 
X 
X 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 81 of 114 
Visit 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
Visit 5 
Visit 6 
Visit 7 
 
Early 
Termination 
Visit12 
Treatment Cycle 
Screening 
Visit 
Subject 
Enrollment1 
During Cycle 
2 
During Cycle 
4 
During Cycle 
7 
During Cycle 
10 
During Cycle 
14  
 
Treatment Cycle 
Day 
 
 
Cycle Day 
1 – 1411 
Cycle Day 
1 - 1411 
Cycle Day 
1 - 14 
Cycle Day 
1 – 14 
Cycle Day 
16-23 
 
Serum Pregnancy 
Test7 
X 
 
 
 
 
 
X 
X 
Dispense Home 
Urine Pregnancy 
Test Kits 
 
X8 
 
 
 
 
 
 
Fasted clinical 
Laboratory tests 
(hematology and 
biochemistry) 
X9 
 
 
 
X10 
 
X9 
X9 
Vital Signs 
X 
X 
X 
X 
X 
X 
X 
X 
Enrollment 
 
X 
 
 
 
 
 
 
Investigational 
Product Dispensing 
 
X 
 
X 
X 
X 
 
 
Investigational 
Product Return and 
Drug Accountability 
 
 
X 
X 
X 
X 
X 
X 
Subject Diary 
Dispensing 
 
X 
 
 
 
 
 
 
Subject Diary 
Review and Return 
 
 
X 
X 
X 
X 
X 
X 
AE Assessment 
 
X 
 
 
 
 
 
 
TEAE Assessment 
 
 
X 
X 
X 
X 
X 
X 
Prior Medication 
X 
X 
 
 
 
 
 
 
Concomitant 
Medication 
 
 
X 
X 
X 
X 
X 
X 

 
 
 
 
 
 
 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 82 of 114 
Visit 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
Visit 5 
Visit 6 
Visit 7 
 
Early 
Termination 
Visit12 
Treatment Cycle 
Screening 
Visit 
Subject 
Enrollment1 
During Cycle 
2 
During Cycle 
4 
During Cycle 
7 
During Cycle 
10 
During Cycle 
14  
 
Treatment Cycle 
Day 
 
 
Cycle Day 
1 – 1411 
Cycle Day 
1 - 1411 
Cycle Day 
1 - 14 
Cycle Day 
1 – 14 
Cycle Day 
16-23 
 
Stop Date of the 
Previous 
Contraceptive 
Method (if any) 
 
 
X 
 
 
 
 
 
Questionnaires 
dispensing 
 
X 
 
 
 
X 
 
 
Questionnaires 
completion check 
 
 
X 
 
 
 
X 
X 
Contraceptive 
Counseling 
 
 
 
 
 
X 
X 
X13 
Follow-up Call 
 
X14 
 
 
 
X15 
 
 
End of Study Form 
 
 
 
 
 
 
X 
X 
Return of 
spontaneous 
menstruation and 
return to fertility16 
 
 
 
 
 
 
 
 
1 Subject enrollment will occur within 45 days after the Screening Visit. 
2 Height will be recorded at Screening Visit only. 
3A written documentation of prior Pap test performed within 18 month before screening is allowed. No Pap test will be performed in subjects less than 20 years of age. 
4 Chlamydia and gonorrhea testing at screening should be performed for all subjects. 
5 Chlamydia and gonorrhea testing during Visits will be performed for subjects who reported a change in sexual partner since last test.  
6 Applies only to the approximately 500 subjects who participate in the Population PK Substudy. 
7 Pregnancy test (serum) also indicated in case of suspicion of pregnancy. 
8 Subject should perform urinary pregnancy test at home just before the first pill intake. Result should be recorded in the diary. 
9 Complete hematology and biochemistry (including glycaemia, glycated hemoglobin, total cholesterol, HDL- and LDL-cholesterol, and triglycerides) (see Appendix 2). 

 
 
 
 
 
 
 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 83 of 114 
10 At Visit 5, the following biochemistry parameters will be assessed: glycaemia, glycated hemoglobin, LDH 1 and LDH 2, total cholesterol, HDL- and LDL-cholesterol, 
triglycerides, renal function (urea and creatinine), GFR, and ionogram (Na, K, Cl, Ca2+, P, HCO3-). 
11 Visit 3 and 4 for the subjects in the Population PK Substudy should be performed between Days 10 and 14 of Cycles 2 and 4. 
12 The Early Termination Visit should occur between 16 and 23 days after the last investigational product intake or immediately if the study product was never started. 
13 In case of early termination or withdrawal of subject who did not undergo a Visit 6: contraceptive counseling should be provided as soon as the site is aware of the subject’s 
desire for termination. 
14 Within 7 days following the expected start of treatment to remind the subject to complete the diary entries. 
15 On the day the subject is expected to start the next contraceptive method (± 1 day) to ensure subject’s compliance. 
16Women who discontinue the study due to a pregnancy wish will be followed up for a maximum of one year after study discontinuation for return of spontaneous menstruation 
and until pregnancy or initiation of a contraceptive method (whichever occurs first). 
AE=adverse event; BMI=body mass index; GFR=glomerular filtration rate; HDL=high-density lipoprotein; LDL=low-density lipoprotein; TEAE=treatment-emergent adverse 
event; LDH=lactate dehydrogenase 
 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 84 of 114 
Appendix 2. 
Clinical Laboratory Evaluations 
Hematology 
Hemoglobin 
Mean cell volume 
Hematocrit 
White blood cell & Differential 
Red blood cell count 
Platelet count 
Serum Chemistries 
Albumin 
Total protein 
Alanine aminotransferase (ALAT) 
Serum creatinine 
Aspartate aminotransferase (ASAT) 
GFR 
Blood urea nitrogen  
Sodium 
Gamma glutamyl transferase (GGT) 
Potassium 
Glucose 
Calcium 
Glycated hemoglobin 
Chloride 
Lactate dehydrogenase (LDH) 1 and LDH 2  Bicarbonate 
Total bilirubin 
Phosphorus 
Lipid Profile 
Total cholesterol 
Triglycerides 
High density lipoprotein cholesterol 
Low density lipoprotein cholesterol 
 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 85 of 114 
Appendix 3. 
Bethesda Pap Smear Classification7 
SPECIMEN TYPE: 
Indicate conventional smear (Pap smear) vs. liquid-based preparation vs. other 
STATEMENT ON SPECIMEN ADEQUACY 
 Satisfactory for evaluation (describe presence or absence of endocervical/transformation 
zone component and any other quality indicators, e.g., partially obscuring blood, 
inflammation, etc.) 
 Unsatisfactory for evaluation (specify reason) 
o Specimen rejected/not processed (specify reason) 
o Specimen processed and examined, but unsatisfactory for evaluation of epithelial 
abnormality because of (specify reason) 
GENERAL CATEGORIZATION (optional) 
 Negative for Intraepithelial Lesion or Malignancy 
 Other: See Interpretation/Result (e.g., endometrial cells in a woman ≥45 years of age) 
 Epithelial Cell Abnormality: See Interpretation/Result (specify ‘squamous’ or ‘glandular’ 
as appropriate) 
INTERPRETATION/RESULT 
NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY 
(When there is no cellular evidence of neoplasia, state this in the General Categorization above and/or 
in the Interpretation/Result section of the report—whether or not there are organisms or other non-
neoplastic findings) 
Non-neoplastic Findings (optional to report) 
 
Non-neoplastic cellular variations 
o Squamous metaplasia 
o Keratotic changes 
o Tubal metaplasia 
o Atrophy 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 86 of 114 
o Pregnancy-associated changes 
 
Reactive cellular changes associated with: 
 Inflammation (includes typical repair) 
o Lymphocytic (follicular) cervicitis 
 Radiation 
 Intrauterine contraceptive device (IUD) 
 
Glandular cells status post hysterectomy 
Organisms 
 Trichomonas vaginalis 
 Fungal organisms morphologically consistent with Candida spp. 
 Shift in flora suggestive of bacterial vaginosis 
 Bacteria morphologically consistent with Actinomyces spp. 
 Cellular changes consistent with herpes simplex virus 
 Cellular changes consistent with cytomegalovirus 
OTHER  
 Endometrial cells (in a woman ≥45 years of age) 
(Specify if “negative for squamous intraepithelial lesion”) 
EPITHELIAL CELL ABNORMALITIES: 
 SQUAMOUS CELL 
 Atypical squamous cells 
o of undetermined significance (ASC-US)   
o cannot exclude HSIL (ASC-H) 
 Low-grade squamous intraepithelial lesion (LSIL) (encompassing:  HPV/ mild 
dysplasia/CIN 1) 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 87 of 114 
 High-grade squamous intraepithelial lesion (HSIL) (encompassing:  moderate and 
severe dysplasia, CIS; CIN 2 and CIN 3) 
 with features suspicious for invasion (if invasion is suspected) 
 Squamous cell carcinoma 
 GLANDULAR CELL 
 Atypical 
o endocervical cells (NOS or specify in comments) 
o endometrial cells (NOS or specify in comments) 
o glandular cells (NOS or specify in comments) 
 Atypical 
o endocervical cells, favor neoplastic 
o glandular cells, favor neoplastic 
 Endocervical adenocarcinoma in situ 
 Adenocarcinoma 
o endocervical 
o endometrial 
o extrauterine 
o not otherwise specified (NOS) 
OTHER MALIGNANT NEOPLASMS: (specify) 
ADJUNCTIVE TESTING 
Provide a brief description of the test method(s) and report the result so that it is easily 
understood by the clinician. 
COMPUTER-ASSISTED INTERPRETATION OF CERVICAL CYTOLOGY 
If case examined by an automated device, specify device and result. 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 88 of 114 
Appendix 4. 
Quality of Life Enjoyment and Satisfaction 
Questionnaire – Short Form (Q-LES-Q-SF) 
 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 89 of 114 
Appendix 5. 
Menstrual Distress Questionnaire (Form C – Cycle)1 
 
Directions:  
The list below shows common symptoms and feelings associated with menstruation. For each 
item, choose the descriptive category below that best describes your experience during each of 
the three time periods indicated. That is, for each item, decide whether you have “no experience 
of symptom”, or whether your experience is “present, mild”, “present, moderate”, “present, 
strong” or “present, severe. Then write the number of the category in the space provided. If 
none of the categories exactly describes your experience, choose the one that most closely 
matches what you feel.  
Be sure to rate every item. When you are finished return the completed form to the person who 
gave it to you.  
 
Descriptive Categories  
0  
No experience of symptom  
1  
Present, mild  
2  
Present, moderate  
3  
Present, strong  
4  
Present, severe  
 
 
 
Most recent 
flow 
Four days 
before 
Remainder of 
cycle 
1. Muscle stiffness 
 
 
 
2. Headache 
 
 
 
3. Cramps 
 
 
 
4. Backache 
 
 
 
5. Fatigue 
 
 
 
6. General aches and pains 
 
 
 
7. Weight gain 
 
 
 
8. Skin blemish or disorder 
 
 
 
9. Painful or tender breasts 
 
 
 
10. Swelling (breasts, abdomen, ..) 
 
 
 
11. Dizziness, faintness 
 
 
 
12. Cold sweats 
 
 
 
13. Nausea, vomiting 
 
 
 
                                                 
1 Copyright © 1968, 1991, 2000, 2010 Rudolf H. Moos. All rights reserved.   

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 90 of 114 
 
Most recent 
flow 
Four days 
before 
Remainder of 
cycle 
14. Hot flashes 
 
 
 
15. Loneliness 
 
 
 
16. Anxiety 
 
 
 
17. Mood swings 
 
 
 
18. Crying 
 
 
 
19. Irritability 
 
 
 
20. Tension 
 
 
 
21. Feeling sad or blue 
 
 
 
22. Restlessness 
 
 
 
23. Insomnia 
 
 
 
24. Forgetfulness 
 
 
 
25. Confusion 
 
 
 
26. Poor judgment 
 
 
 
27. Difficulty concentrating 
 
 
 
28. Distractible 
 
 
 
29. Minor Accidents 
 
 
 
30. Poor motor coordination 
 
 
 
31. Poor school/work performance 
 
 
 
32. Take naps, stay in bed 
 
 
 
33. Stay at home 
 
 
 
34. Avoid social activities 
 
 
 
35. Decreased efficiency 
 
 
 
36. Affectionate 
 
 
 
37. Orderliness 
 
 
 
38. Excitement 
 
 
 
39. Feelings of well-being 
 
 
 
40. Bursts of energy, activity 
 
 
 
41. Feelings of suffocation 
 
 
 
42. Chest pains 
 
 
 
43. Ringing in the ears 
 
 
 
44. Heart pounding 
 
 
 
45. Numbness, tingling 
 
 
 
46. Blind Spots, fuzzy vision 
 
 
 
 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 91 of 114 
Appendix 6. 
Sponsor Signatures 
Study Title: 
A Multicenter, Open-label, Single-Arm Study to Evaluate the 
Contraceptive Efficacy and Safety of a Combined Oral 
Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone 
Study Number: 
MIT-Es0001-C302 
Original protocol 
date: 
07 June 2016 – Version 1.1 
Amendment 1.0 
date: 
14 December 2016 
Amendment 1.1 
10 July 2017 
date 
 
 
 
This clinical study protocol was subject to critical review and has been approved by the 
Sponsor. The following personnel contributed to writing and/or approving this protocol: 
 
 
 
 
Signature: 
 
 
 
 
 
 
 
Date:   
_________ 
Marie Mawet 
Medical Advisor 
 
 
 
 
 
Signature:  
 
 
 
 
 
 
 
Date:   
_________ 
Mitchell Creinin 
Senior Medical Advisor  
 
 
 
 
Signature:  
 
 
 
 
 
 
 
Date:   
_________ 
Sophie Ledant 
Clinical Project Leader 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 92 of 114 
 
 
 
 
 
 
 
Signature:  
 
 
 
 
 
 
 
Date:   
_________ 
Barbara Bovy 
Qualified Person for Pharmacovigilance 
 
 
 
 
Signature:  
 
 
 
 
 
 
 
Date:   
_________ 
Francoise Bruyère 
Clinical Manager 
 
 
 
 
 
 
Signature:  
 
 
 
 
 
 
 
Date:   
_________ 
Valérie Gordenne 
Chief Scientific Officer 
 
 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 93 of 114 
Appendix 7. 
Contract Research Organization Signatures 
Study Title: 
A Multicenter, Open-label, Single-Arm Study to Evaluate the 
Contraceptive Efficacy and Safety of a Combined Oral 
Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone 
Study Number: 
MIT-Es0001-C302 
Original protocol 
date: 
07 June 2016 – Version 1.1 
Amendment 1.0 
date: 
14 December 2016 
Amendment 1.1 
10 July 2017 
date 
 
 
 
 
 
This clinical study protocol was subject to critical review and has been approved by PRA 
Health Sciences.  
 
 
 
 
 
Signature:  
 
 
 
 
 
 
 
Date:   
_________ 
Jess Read 
Principal Biostatistician 
PRA Health Sciences 
 
 
 
 
 
Signature:  
 
 
 
 
 
 
 
Date:   
_________ 
Vijaya Vundurti 
Drug Safety Associate 
PRA Health Sciences 
 
 
 
 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 94 of 114 
 
 
 
 
 
Signature:  
 
 
 
 
 
 
 
Date:   
_________ 
Douglas Stewart 
Lead Data Manager 
PRA Health Sciences 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 95 of 114 
Appendix 8. 
Investigator Signature 
Study Title: 
A Multicenter, Open-label, Single-Arm Study to Evaluate the 
Contraceptive Efficacy and Safety of a Combined Oral 
Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone 
Study Number: 
MIT-Es0001-C302 
Original protocol 
date: 
07 June 2016 – Version 1.1 
Amendment 1.0 
date: 
14 December 2016 
Amendment 1.1 
date 
10 July 2017 
 
This clinical study protocol was reviewed and has been approved by the Investigator. 
 
Name:__________________________________________ 
 
Function: _______________________________________ 
 
Institution:_______________________________________ 
 
 
Signature:  
 
 
 
 
 
 
 
Date:  
 
 
 
 
 
 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 96 of 114 
Appendix 9. 
Protocol Amendment - Summary of changes 
Modified sections in Protocol: MIT-Es0001-C302 Amendment Version 1.0 
This section summarizes changes that have been performed between original protocol (Final 
Version 1.1 (07 June 2016) and Amendment Version 1.0 (14 December 2016). 
 
Note: wherever applicable, deleted text has been crossed out and added text has been 
printed in bold and italic characters. 
 
2 
SYNOPSIS 
Other Secondary Objectives: 
[…] 
4. To assess the effect of various individual characteristics/ covariates (body weight, race, 
and smoking, and fed/fasted condition) on the pharmacokinetics (PKs) of 15 mg E4/3 mg 
DRSP (Population PK Substudy). 
[…] 
 Eligibility criteria: 
Exclusion Criteria 
A subject will be excluded from participation if she meets any of the following criteria: 
[…] 
7. Smoking nicotine-containing products if ≥ 35 years old, at screening. 
16. Complicated valvular heart disease (pulmonary hypertension, arterial atrial fibrillation, 
subacute bacterial endocarditis). 
25. History of COC-related cholestasis. 
[…] 
Statistical Methods: 
[…] 
 
Additional Summaries: 
[…] 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 97 of 114 
 Population PK model (using plasma E4 and DRSP concentration data from a subset 
of approximately 500 subjects). PK parameters will include, but not be limited to: 
o […] 
o Relative bioavailability for fed vs fasted state 
o […] 
Initial estimates of PK parameters (e.g., CL/F, V/F, tlag) will be determined using 
exploratory compartmental analyses. These estimates will be employed to build an 
appropriate population PK model. The primary parameters will include (but not be limited 
to) Cmax, Tmax, AUCtau, and t1/2 CL/F, V/F, tlag and relative bioavailability for fed vs fasted. 
The impact of individual characteristics (body weight, race, and smoking, and fed/fasted 
condition) on the PK parameters will be explored and included in the population model if 
significant.  
[…] 
 
 
7 
INTRODUCTION 
7.1 Background 
[…] 
The potent synthetic estrogen, ethinylestradiol (EE), is the most frequently used estrogen in 
COCs. EE is easily observed absorbed when administered orally. 
[…] 
8  
STUDY OBJECTIVES 
 
8.3 Other Secondary Objective(s) 
 4. To assess the effect of various individual characteristics/ covariates (body weight, race,  
and smoking, and fed/fasted condition) on the PKs of 15 mg E4/3 mg DRSP (Population PK 
Substudy). 
 
9 
INVESTIGATIONAL PLAN 
9.1 Overall Study Design and Plan 
[…] 
The total duration of the study, including the screening, will range from 382 387 to 447 467 
days for the participating subjects, which is approximately a year and one month. 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 98 of 114 
[…] 
Population PK will be assessed using plasma E4 and DRSP concentration data from a subset 
of approximately 500 subjects to address the relationship between E4 and DRSP PK 
parameters and various individual characteristics (e.g., body weight, race, and smoking, and 
fed/fasted condition). Blood samples for PK analysis will be obtained at Visits 3 and 4 between 
Days 10 and 14 of Cycles 2 and 4 (section 9.6.4.2). 
9.3 Selection of Study Population 
[…] 
9.3.2 Exclusion Criteria 
A subject will be excluded from participation if she meets any of the following criteria: 
2. […] 
7. Smoking nicotine-containing products if ≥ 35 years old, at screening. 
16. Complicated valvular heart disease (pulmonary hypertension, arterial atrial fibrillation, 
subacute bacterial endocarditis). 
19. Presence or history of migraine with aura at any age or migraine without aura if >  35 
years old. 
25. History of COC-related cholestasis. 
26-42. […] 
9.4 Study Treatment 
9.4.4 Selection of Doses and Timing of Administration in the Study 
9.4.4.1 Instructions for starting the first pack of tablets 
 Women who did not use any contraceptive method or who used a barrier 
contraceptive method will be instructed to begin the investigational product on 
the first day of the next menstrual bleeding. Starting on Days 2-5 is also 
allowed, but a condom must be used until the subject has completed 7 days of 
uninterrupted active tablet intake. If the menstrual cycle prior to start of first 
pack of tablets is longer than 35 days or shorter than 21 days, the subject 
should not start the investigational product and will be withdrawn from the 
study (section 13.4). The subject should contact the study staff as soon as 
possible to schedule an Early Termination Visit (section 9.5.4) and to discuss 
an alternative contraception to use (section 9.6.4.9).                                                                 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 99 of 114 
 […] 
 Women switching from an injectable hormonal method of contraception will 
start the investigational product on the first day of the spontaneous menstrual 
bleeding following an interval after the last injection, which can vary 
depending of the form:  
- 10 months after the injection of a product with a 3-month duration, ; 
- 6 months after the injection of a product with a 2-month duration and;  
- 3 months after the injection of a product with a 1-month duration.  
Starting on Days 2-5 is also allowed, but a condom must be used until the 
subject has completed 7 days of uninterrupted active tablet intake.   
 Women switching from an intrauterine or dermally implantable contraceptive 
will start the investigational product on the day of removal. A condom must be 
used until the subject has completed 7 days of uninterrupted active tablet 
intake. 
[…] 
9.4.4.2 Dosing Instructions 
[…] 
 […] 
 Return all blister packs to site personnel at the following visit. 
 
9.4.4.3 Instructions in case of missed tablet(s) or in conditions potentially reducing the 
contraceptive efficacy 
If the subject has vomiting or diarrhea within 4 hours of tablet intake, she should take 
another tablet from the extra pack as a replacement. 
If the subject inadvertently misses one or more of the tablets or 
 In case of vomiting within 4 hours after the tablet intake or, 
 In case of diarrhea within 4 hours after the tablet intake, 
the following instructions must be followed:6   
 […] 
 If two or more consecutive active pink tablets have been missed (≥ 48 hours 
since a tablet should have been taken): 
o If between Day 1 & Day 17: 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 100 of 114 
 […] 
 Consider emergency contraception as per current practice 
if the woman had unprotected intercourse during the 
missed pill interval. 
o […] 
 
 A new pack of tablets should be started immediately after the day the last white 
tablet was taken. There should be no interruption between two blister packs.  
Anytime a subsequent cycle of the product/pack is started later than the day 
following administration of the last white tablet, the subject should use condoms 
until she has taken pink tablets daily for 7 consecutive days. 
 Return all blister packs to site personnel at the following visit. 
 
 
9.5 Study Activities 
[…] 
9.5.1 Visit 1: Screening Visit  
[…] 
Potential subjects will be screened according to the inclusion and exclusion criteria within 30 
45 days prior to the subject enrollment visit (Visit 2). Subjects who were eligible for the study 
but did not enroll within 45 days of screening (Visit 1) can be re-screened. Re-screening 
requires all Visit 1 assessments to be repeated. The Investigator will maintain a log of all 
subjects screened for participation and record the reason(s) for excluding potential subjects. 
[…] 
9.5.2 Visit 2: Subject Enrollment 
The Visit 2 will occur within 30 45 days after the Screening Visit (Visit 1), when the entire 
laboratory results of the subject have been received. 
[…] 
During Visit 2, the following procedures will be performed: 
1-10. […] 
11. Schedule or confirm the next study visit and the follow-up phone call; 
12. […] 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 101 of 114 
13. Instruct the subject to contact the site immediately if she decides to discontinue the 
investigational product and, if possible, to not discontinue the investigational product before 
contacting the site; 
14. […] 
9.5.3 Treatment Period (from Cycle 1 Day 1 until Cycle 13 Day 28) 
9.5.3.1 Visit 3 (Cycle 2, between Day 1 and Day 14) 
[…] 
12. Instruct the subject to contact the site immediately if she decides to discontinue the 
investigational product and, if possible, to not discontinue the investigational product before 
contacting the site. 
9.5.3.2 Visit 4 (Cycle 4, between Day 1 and 14) 
[…] 
12. Instruct the subject to contact the site immediately if she decides to discontinue the 
investigational product and, if possible, to not discontinue the investigational product before 
contacting the site. 
9.5.3.3 Visit 5 (Cycle 7, between Day 1 and 14) 
[…] 
12. Instruct the subject to contact the site immediately if she decides to discontinue the 
investigational product and, if possible, to not discontinue the investigational product before 
contacting the site. 
9.5.3.4 Visit 6 (Cycle 10, between Day 1 and 14) 
[…] 
13. Instruct the subject to contact the site immediately if she decides to discontinue the 
investigational product and, if possible, to not discontinue the investigational product before 
contacting the site. 
9.5.3.5 Visit 7 (Cycle 14, between Day 16 and 23), End of Treatment Visit 
1-10. […] 
11. Complete the End of Study Termination Form. 
 
9.5.4 Early Termination Visit  
In case of early termination or withdrawal of subject (see Section 13.5), the procedures listed 
in Visit 7 (see Section 9.5.3.5) will be performed and Treatment Discontinuation Form will be 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 102 of 114 
completed. In addition, the subject will be counseled about the next contraceptive method to 
use (see Section 9.6.4.9). 
A subject who desires early termination or is withdrawn from the study after the enrollment 
visit (Visit 2) (see Section 13.4) will require an Early Termination Visit. 
 Any subject who contacts the study site with a desire to discontinue study 
participation should be instructed at each visit to contact the study staff before 
discontinuing the study drug to be counseled about alternative contraception to use 
prior to the Early Termination Visit (see Section 9.6.4.9).  Study sites may provide 
any prescription or non-prescription contraceptive to the subject as is medically 
appropriate per local standard of care other than an IUD or implant. If necessary, 
an unscheduled visit can occur to provide contraception (see Section 9.5.5). 
 A subject who presents to the study site for a scheduled visit and desires to 
discontinue study participation or is withdrawn from the study at that visit should be 
counseled about alternative contraception to use prior to the Early Termination Visit 
(see Section 9.6.4.9). Study sites may provide any prescription or non-prescription 
contraceptive to the subject as is medically appropriate per local standard of care 
other than an IUD or implant. 
 A subject who presents to the study site for a scheduled visit who has not taken the 
study product for 16 days or more should have the scheduled visit procedures and 
the Early Termination Visit procedures completed at that time. The subject should 
be counseled about alternative contraception (see Section 9.6.4.9). Study sites may 
provide any prescription or non-prescription contraceptive to the subject as is 
medically appropriate per local standard of care. 
An Early Termination Visit should occur between 16 and 23 days after the last 
investigational product intake or immediately if the investigational product was never 
started. The procedures listed in Visit 7 (see Section 9.5.3.5) will be performed and the End 
of Study Form will be completed.  
[…] 
9.5.5 Unscheduled Visit 
At any time of the study, an Unscheduled Visit could occur in case of suspicion of pregnancy 
based on a positive pregnancy test performed at home by the subject or, in case the Investigator 
judges it necessary to examine a subject who would present a potential significant adverse 
event in the Investigator’s opinion, or if alternative contraception is needed for a subject 
planning early termination. Additional assessments can be performed at the Investigator’s 
discretion. 
9.6 Study Variables and Procedure Descriptions 
9.6.2 Efficacy assessments 
 9.6.2.2 Pregnancy Reporting 
[…] 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 103 of 114 
All on-treatment pregnancies identified during the course of the study in a subject who was 
using the investigational product will be monitored to completion, i.e., approximately 9 month 
follow-up in the case of live birth or until outcome information is obtained. […].                              
If a subject becomes pregnant and states she never started the investigational product, the 
pregnancy does not have to be monitored if the subject returns all of the investigational 
product (proving she never started the investigational product). 
 
9.6.3 Safety variables 
 
9.6.3.6 Gynecological Examination, Chlamydia test, Gonorrhea test and Cervical Cytology 
[…] 
Enrollment of a subject with an ASC-US ASCUS interpretation is permitted if the subject is 
less than 21 years of age or HPV reflex test is negative for high-risk oncogene virus. 
[…] 
 
9.6.4.2 Population Pharmacokinetic Substudy 
Population PK will be assessed using plasma E4 and DRSP concentration data from a subset 
of approximately 500 subjects to address the relationship between PK parameters and various 
individual characteristics (e.g., body weight, race, and smoking, and fed/fasted condition). 
Blood samples for PK analysis will be obtained at Visits 3 and 4 between Days 10 and 14 of 
Cycles 2 and 4.  
[…] 
Two PK samples will be taken from the subjects in the Population PK Substudy at Visits 3 and 
4. All subjects included in the Substudy will provide a sample for PK analysis at the time they 
check into the site (PK sampling 1). An additional blood sample (PK sampling 2) will be 
collected approximately two hours after the first sample.  
Depending on the time scheduled for the study site visit (Visit 3 & 4), subjects will be 
instructed on when they need to take their medication – either as usually done at home or 
on site. 
- 
If the appointement is scheduled in the morning and the subject usually takes her 
study medication in the morning, she should take it at the study site. One blood 
sample will be taken before dosing and the second blood sample will be taken within 
2-hour postdose.  
- 
If the appointement is scheduled in the morning and the subject usually takes her 
study medication in the evening, she should take it in the evening before the visit at 
their regular time. The subject should record the time of the dosing in the Diary.  

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 104 of 114 
- 
A Subject who usually takes her study medication during the day should take it at 
usual time and come to the site when possible to have the 2 blood samples taken. The 
subject should record the time of dosing in the Diary. 
The exact times of following timings the last study medication dosing and the PK sampling 
will be recorded by the site personnel in the eCRF: 
- 
The exact times of the last study medication dosing and the PK samplings 1 and 2.  
- 
The time of the last meal intake before the last study medication dosing before study 
visit. 
 
[…] 
9.6.4.9 Contraceptive counseling 
At Visit 6 and at the Early Termination Visit in case of premature study termination, the 
subject will be counseled about her future contraception. The choice of the contraceptive 
method is left at to the Investigator’s discretion.  
A subject who desires early termination or is withdrawn from the study (see Section 13.4) 
after the enrollment visit (Visit 2) will be counseled about future contraception. 
 Any subject who contacts the study site with a desire to discontinue study 
participation should be instructed at each visit to contact the study staff before 
discontinuing the study drug to be counseled about alternative contraception to use 
prior to the Early Termination Visit.  Study sites may provide any prescription or 
non-prescription contraceptive to the subject as is medically appropriate per local 
standard of care other than an IUD or implant. If necessary, an unscheduled visit 
can occur to provide contraception (see Section 9.5.5). 
 A subject who presents to the study site for a scheduled visit and desires to 
discontinue study participation or is withdrawn from the study at that visit should be 
counseled about alternative contraception to use prior to the Early Termination Visit. 
Study sites may provide any prescription or non-prescription contraceptive to the 
subject as is medically appropriate per local standard of care other than an IUD or 
implant. 
 
A subject who presents to the study site for a scheduled visit who has not taken the 
study product for 16 days or more should have the scheduled visit procedures and 
the Early Termination Visit procedures completed at that time. The subject should 
be counseled about alternative contraception. Study sites may provide any 
prescription or non-prescription contraceptive to the subject as is medically 
appropriate per local standard of care. 
[…] 
9.6.4.11 Subjects’ well-being 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 105 of 114 
[…] 
The baseline questionnaires will be given to the subject at Visit 2. The subject will be instructed 
to fill them in at home on or before the first day of study medication intake (Day 1). At the 
next visit, the study site personnel will ensure for the questionnaire completion. 
9.6.4.12 Return of spontaneous menstruation and return to fertility 
Each woman who discontinues the study early due to a pregnancy wish will be followed after 
study treatment discontinuation to evaluate return of spontaneous menstruation and return of 
fertility.  
They will be contacted by phone every 6-8 weeks for a maximum of one year after study 
discontinuation. 
[…] 
12 
PLANNED STATISTICAL METHODS 
12.6 Other Assessments or Analyses 
12.6.7 Quality of Life 
[…] 
The absolute values and change from baseline for the scores for pain, water retention, 
autonomic reactions, negative affect, impaired concentration, behaviour change, arousal and 
control will be summarized descriptively by visit. 
[…] 
12.6.9 Population Pharmacokinetic Substudy 
Plasma concentration data for E4 and DRSP will be summarized using descriptive statistics by 
cycle and sampling time range (ranges will be defined in the Statistical Analysis Plan) for the 
PK population. Descriptive summaries will be provided overall and by race, BMI categories 
(< 30, ≥ 30), and smoking status (smokers, non-smokers), and fed/fasted condition. 
Additionally, concentration data will be displayed graphically with regression lines overall, 
and by race, BMI categories, and smoking status for each cycle. 
Individual plasma concentration-time data will be pooled for the PK analyses. Initially, the 
data will be subjected to exploratory compartmental analysis to determine the basic primary 
parameters such as: 
 
[…] 
 Relative bioavailability for fed vs fasted state. 

 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 106 of 114 
The initial estimates obtained from the exploratory analyses will be employed using non linear 
mixed effect modeling Bayesian analysis to build an appropriate population PK model. The 
analyzed parameters will include, but not be limited to: 
[…] 
13 
STUDY MANAGEMENT 
13.4 Withdrawal of Subjects 
[…] 
If a subject is withdrawn from the study following the start of study drug after enrolment visit 
(Visit 2), all Visit 7 assessments should be completed (see Section 9.5.3.5) and the subject 
should be counseled about alternative contraception to use (see Section 9.6.4.9). Subjects 
withdrawn from the study will not be replaced. 
 
17 
Appendices 

 
 
 
 
 
 
 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 107 of 114 
 
Appendix 1 Study Schedule of Events 
Table 2: Schedule of Events 
Visit 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
Visit 5 
Visit 6 
Visit 7 
 
Early 
Termination 
Visit12 
Treatment Cycle 
Screening 
Visit 
Subject 
Enrollment1 
During Cycle 
2 
During Cycle 
4 
During Cycle 
7 
During Cycle 
10 
During Cycle 
14 / Early 
termination 
Visit 
 
Treatment Cycle 
Day 
 
 
Cycle Day 
1 – 1411 
Cycle Day 
1 - 1411 
Cycle Day 
1 - 14 
Cycle Day 
1 – 14 
Cycle Day 
16-23 
 
Informed Consent 
X 
 
 
 
 
 
 
 
Inclusion/Exclusio
n Criteria 
X 
X 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
Medical and 
surgical History 
X 
 
 
 
 
 
 
 
Gynecological 
History 
X 
 
 
 
 
 
 
 
Physical 
Examination 
X 
 
 
 
 
 
X 
X 
Weight, Height 
and BMI2 
X 
 
 
X 
X 
 
X 
X 
Gynecological 
Examination 
(including breast) 
X 
 
 
 
 
 
X 
X 
Cervical Cytology 
(Pap)3 
X 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 108 of 114 
Visit 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
Visit 5 
Visit 6 
Visit 7 
 
Early 
Termination 
Visit12 
Treatment Cycle 
Screening 
Visit 
Subject 
Enrollment1 
During Cycle 
2 
During Cycle 
4 
During Cycle 
7 
During Cycle 
10 
During Cycle 
14 / Early 
termination 
Visit 
 
Treatment Cycle 
Day 
 
 
Cycle Day 
1 – 1411 
Cycle Day 
1 - 1411 
Cycle Day 
1 - 14 
Cycle Day 
1 – 14 
Cycle Day 
16-23 
 
Chlamydia 
Testing 
X4 
X5 
X5 
X5 
X5 
X5 
 
 
Gonorrhea 
Testing 
X4 
X5 
X5 
X5 
X5 
X5 
 
 
Blood sample for 
Population PK 
Substudy6 
 
 
X 
X 
 
 
 
 
Serum Pregnancy 
Test7 
X 
 
 
 
 
 
X 
X 
Dispense Home 
Urine Pregnancy 
Test Kits 
 
X8 
 
 
 
 
 
 
Fasted clinical 
Laboratory tests 
(hematology and 
biochemistry) 
X9 
 
 
 
X10 
 
X9 
X9 
Vital Signs 
X 
X 
X 
X 
X 
X 
X 
X 
Enrollment 
 
X 
 
 
 
 
 
 
Investigational 
Product 
Dispensing 
 
X 
 
X 
X 
X 
 
 
Investigational 
Product Return 
and Drug 
Accountability 
 
 
X 
X 
X 
X 
X 
X 

 
 
 
 
 
 
 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 109 of 114 
Visit 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
Visit 5 
Visit 6 
Visit 7 
 
Early 
Termination 
Visit12 
Treatment Cycle 
Screening 
Visit 
Subject 
Enrollment1 
During Cycle 
2 
During Cycle 
4 
During Cycle 
7 
During Cycle 
10 
During Cycle 
14 / Early 
termination 
Visit 
 
Treatment Cycle 
Day 
 
 
Cycle Day 
1 – 1411 
Cycle Day 
1 - 1411 
Cycle Day 
1 - 14 
Cycle Day 
1 – 14 
Cycle Day 
16-23 
 
Subject Diary 
Dispensing 
 
X 
 
 
 
 
 
 
Subject Diary 
Review and 
Return 
 
 
X 
X 
X 
X 
X/ 
X 
AE Assessment 
 
X 
 
 
 
 
 
 
TEAE Assessment 
 
 
X 
X 
X 
X 
X 
X 
Prior Medication 
X 
X 
 
 
 
 
 
 
Concomitant 
Medication 
 
 
X 
X 
X 
X 
X 
X 
Stop Date of the 
Previous 
Contraceptive 
Method (if any) 
 
 
X 
 
 
 
 
 
Questionnaires 
dispensing 
 
X 
 
 
 
X 
 
 
Questionnaires 
completion check 
 
 
X 
 
 
 
X 
 
 X 
Contraceptive 
Counseling 
 
 
 
 
 
X 
X 
X13 
Follow-up Call 
 
X1314 
 
 
 
X1415 
 
 
End of Study 
Form 
 
 
 
 
 
 
X 
X 

 
 
 
 
 
 
 
 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 110 of 114 
Visit 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
Visit 5 
Visit 6 
Visit 7 
 
Early 
Termination 
Visit12 
Treatment Cycle 
Screening 
Visit 
Subject 
Enrollment1 
During Cycle 
2 
During Cycle 
4 
During Cycle 
7 
During Cycle 
10 
During Cycle 
14 / Early 
termination 
Visit 
 
Treatment Cycle 
Day 
 
 
Cycle Day 
1 – 1411 
Cycle Day 
1 - 1411 
Cycle Day 
1 - 14 
Cycle Day 
1 – 14 
Cycle Day 
16-23 
 
Return of 
spontaneous 
menstruation and 
return to 
fertility1516 
 
 
 
 
 
 
 
 
1 Subject enrollment will occur within 30 45 days after the Screening Visit. 
[…] 
12 The Early Termination Visit should occur between 16 and 23 days after the last investigational product intake or immediately if the study product was never started. 
1213 In case of early termination or withdrawal of subject who did not undergo a Visit 6: contraceptive counseling should be provided as soon as the site is aware of the subject’s 
desire for termination. 
1314 Approximately Within 7 days following the expected start of treatment to remind the subject to complete the diary entries. 
1415 […] 
1516 […] 
 
 

 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 111 of 114 
Appendix 6 Sponsor Signatures 
 
[…] 
 
Signature: 
 
 
Date:  
 
Karina Putineanu 
Head of Clinical Development 
 
 
Signature: 
 
 
Date:  
 
Linda Lebon 
Regulatory Affairs & Drug Development Expert 
 
[…] 
 
Modified sections in Protocol: MIT-Es0001-C302 Amendment Version 1.1 
This section summarizes changes that have been performed between Amendment Version 1.0 
(14 December 2016) and Amendment Version 1.1 (10 July 2017) 
 
Note: wherever applicable, deleted text has been crossed out (double strikethrough) and 
added text has been printed in bold, underlined and italic characters. 
2 SYNOPSIS 
Study Population:  
Approximately 2000 healthy female subjects at risk for pregnancy, between 16 and 50 years 
old, inclusive (at the time of screening), and requesting contraception will be enrolled in the 
study and initiate the investigational product. In total 1800 subjects will be 16 to 35 years 
old, inclusive (at the time of screening). Recruitment may be stopped when 2000 subjects 
have been enrolled initiated the investigational product if the required number of subjects 
for the primary analysis (1800 subjects in the age group up to and including 35 years) has 
been reached. Recruitment in the age group > 35 years will be stopped when 200 subjects 
have been enrolled initiated the investigational product. Approximately 500 of these 
subjects will be included in the Population PK Substudy. 
Study Locations:  
This clinical study will be conducted in up to approximately 70 80 centers in North America 
(United States of America and Canada).  
[…] 
Duration of the study:   

 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 112 of 114 
Overall treatment duration is up to thirteen 28-day cycles, i.e., 12 months. 
[…] 
Statistical Methods: 
[…] 
For Pearl index calculations, thirteen 28-day cycles constitute one woman-year. 
[…] 
 
6 STUDY ADMINISTRATIVE STRUCTURE 
The study will be performed in approximately 70 80 centers in North America with 
approximately 90% of subjects in United States of America and 10% of subjects in Canada.   
9 INVESTIGATIONAL PLAN 
9.1 Overall Study Design and Plan 
[…] 
Approximately 2000 healthy female subjects at risk for pregnancy, between 16 and 50 years 
old (inclusive, at the time of screening), and requesting contraception will be enrolled in the 
study and initiate the investigational product. In total, 1800 subjects will be 16 to 35 years 
old (inclusive). Recruitment may be stopped when 2000 subjects have been enrolled initiated 
the investigational product if the required number of subjects for the primary analysis (1800 
subjects in the age group up to 35 years) has been reached. Recruitment in the age group > 35 
years will be stopped when 200 subjects have been enrolled initiated the investigational 
product. 
Eligible subjects will be treated with 15 mg E4/3 mg DRSP for up to 13 consecutive cycles. 
[…] 
9.4 Study Treatment 
9.4.4 Selection of Doses and Timing of Administration in the Study 
[…] 
This 28-day cyclic regimen must be taken for up to 13 consecutive cycles. The treatment must 
be taken once daily at approximately the same time of the day. 
[…] 
9.5 Study Activities 
9.5.2 Visit 2: Subject Enrollment 
[…] 

 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 113 of 114 
13. Instruct any subject not on a hormonal contraceptive and who does not start the 
investigational product at the enrollment visit to contact the site immediately if her next 
menses occurs at earlier than 21 days or is delayed such that her cycle length exceeds 35 
days, and that she should not start the investigational product if either of these happens; 
 […] 
12 PLANNED STATISTICAL METHODS 
12.1 Determination of Sample Size 
[…].  If a not at risk cycle rate of 20% and a dropout rate of approximately 45% (assuming that 
we have an average of 4 cycles for subjects that discontinue) are assumed, approximately 1800 
16 to 35 year old subjects need to be enrolled and initiate the investigational 
product.  Additionally, it is planned to enroll for a maximum of 200 subjects > 35 years to be 
enrolled and initiate the investigational product. Therefore, in total, approximately 2000 
subjects will be enrolled in the study and initiate the investigational product. Additionally, a 
subset of approximately 500 subjects will be enrolled in the PK Substudy. 
12.4 Efficacy Analyses 
[…] 
12.4.2 Statistical Analysis 
12.4.2.2 Life-Table Rates 
[…] 
Cumulative probabilities of pregnancy and 95% CIs will be calculated based on Kaplan-Meier 
estimates for through Cycle 13. Additionally, the estimated survivor function against time 
(cycle) will be provided. 
 
Appendix 6. Sponsor Signatures 
 
 
Signature: 
 
 
 
 
 
Date:  
 
Karina Putineanu 
Head of Clinical Development 
Françoise Bruyère 
Clinical Manager 
 
Appendix 7. Contract Research Organization Signatures 
 
 
Signature: 
 
 
 
 
 
Date:  
 
Lyn Taylor 

 
 
 
 
 
Study MIT-Es0001-C302 
Amendment Final Version 1.1 
Confidential 
Page 114 of 114 
Jess Read 
Principal Biostatistician 
PRA Health Sciences 
 
Signature: 
 
 
 
 
 
Date:  
 
Ramdas Kanase 
Vijaya Vundurti 
Drug Safety Associate 
PRA Health Sciences 
 
Signature: 
 
 
 
 
 
Date:  
 
LaTonya Bufford 
Douglas Stewart  
Lead Data Manager 
PRA Health Sciences